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Abstract
Staphylococcus aureus is a human pathogen capable of causing infections that range from
mild skin and soft tissue infections to severe infections of the bone, muscle, heart, and lung.
To survive and thrive in such diverse host environments, S. aureus must maintain sufficient
levels of metabolites and cofactors to support virulence determinant production and
replication. The branched-chain amino acids (BCAAs; Ile, Leu, Val) represent an important
group of nutrients for S. aureus metabolism, as they are required for protein synthesis and
synthesis of membrane branched-chain fatty acids (BCFAs), which are important for S.
aureus environmental adaptation. Moreover, the BCAAs are co-repressors for the global
transcriptional regulator CodY, which coordinates expression of nutrient scavenging and
synthesis systems, as well as virulence genes, upon depletion of both BCAAs and GTP. The
requirement of BCAAs for both S. aureus replication and niche adaptation necessitates that it
either synthesize these nutrients or acquire them from the environment. Although S. aureus
possesses the genes required for BCAA biosynthesis, it was previously reported as
auxotrophic for Leu and Val. Further, BCAAs are presumed to be limited at host infection
sites. In this study, we used a genetic approach to examine the mechanisms of BCAA
acquisition in S. aureus and determine the conditions where BCAA synthesis is turned on.
We found that S. aureus necessitates two BCAA transporters, BrnQ1 and BcaP, for growth
and BCFA synthesis, with the requirement for BCAA transport in vivo depending on the
infection site. We further determined that S. aureus does indeed engage in BCAA
biosynthesis, but it represses synthesis in the presence of an exogenous BCAA source. This
source preference is regulated by at least two mechanisms that sense exogenous levels of
BCAAs, resolving the conundrum of why S. aureus appeared auxotrophic for Leu and Val.
Altogether, this research defines the major pathways of BCAA acquisition in S. aureus and
reveals the niche-specific requirement of nutrient acquisition pathways for S. aureus
virulence, highlighting the impressive adaptability of S. aureus to nutrient deprivation and its
sophistication at exploiting host nutrient sources.
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Chapter 1

1

Introduction

Staphylococcus aureus is a significant human pathogen that imparts tremendous burden on
human health. This burden is the result of widespread S. aureus colonization on the skin and
in the nares of the healthy population, the diversity of its infectious capability, from mild skin
infections in healthy individuals to invasive infections of nearly every body site in
susceptible populations, and the emergence of antibiotic-resistant strains (1–3). Although
decades of research have detailed a profusion of virulence strategies important for S. aureus
pathogenesis (4, 5), an incomplete picture remains of how S. aureus maximizes its virulence
potential in various host environments, which each present a unique set of challenges for S.
aureus to overcome. Continued investigation into the basic biology of these aspects of S.
aureus pathogenesis are therefore needed to uncover how this pathogen responds to changes
in its environment and how it coordinates the employment of virulence strategies to adapt to
these changes. Such efforts will serve as the foundation for the rational development of novel
therapeutics to treat infections and reduce the burden of S. aureus disease.

1.1 The Staphylococci
S. aureus is a facultative anaerobe, Gram-positive bacterium that belongs to the
Staphylococcus genus, which is composed of 47 species and 23 subspecies and includes
opportunistic human and non-human pathogens of medical and veterinary importance (6).
Staphylococci are divided into two categories based on their ability to coagulate plasma, a
phenotypic trait that has proved advantageous in a clinical setting for differentiating between
the most pathogenic human-associated staphylococci, S. aureus, which is coagulase-positive,
from the less pathogenic coagulase-negative staphylococci (CoNS). The test indicates the
presence of the coagulase enzyme, which converts fibrinogen to fibrin. S. aureus produces
two forms, a secreted coagulase and a cell-wall associated coagulase. The phenotypic trait is
shared by some animal-associated staphylococci, which can lead to misclassification of
isolates as S. aureus in a veterinary setting.
CoNS are part of the normal microbiota of animals and human. In humans, the CoNS
colonize the skin, with the spatial habitat occupied (i.e. head, arms, legs, axillae, and groin
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area) dependent on the species (6). Some species, including Staphylococcus caprae,
Staphylococcus epidermidis, and Staphylococcus warneri also colonize the nasopharynx. In a
health-care setting, the CoNS are recognized as significant opportunistic pathogens,
representing the third most common cause of bloodstream infections (7). Populations at most
risk

of

infection

include

the

elderly,

premature

newborns,

chronically

ill/immunocompromised, and patients that have inserted or implanted medical devices, which
provide an avenue for CoNS entry into the bloodstream because of a breach in the epithelial
barrier and/or colonization of the device (6). Depending on the location of the device,
systemic spread of CoNS can lead to abscesses, endocarditis, meningitis or sepsis (8). S.
epidermidis is the most frequent isolate from CoNS infections, followed by Staphylococcus
hominis, Staphylococcus haemolyticus and Staphylococcus capitis (6, 8). Staphylococcus
lugdunensis represents a serious causative agent of infective endocarditis, and although
isolated less frequently than the leading cause, S. epidermidis, it causes particularly
aggressive infections (9, 10).

1.1.1

Staphylococcus aureus

The ecological niche of S. aureus resembles that of CoNS, the skin and nasopharynx (2). The
most frequent site of carriage is the anterior nares, with approximately 30% of the population
carrying S. aureus in the nose (11). The carrier status serves as a reservoir for infection of
colonized individuals as well as individuals within direct contact, best exemplified by
outbreaks in athletes and the military (12–17). The prevalence of S. aureus in the healthy
population, coupled with its highly invasive capacity, contribute to its success as the leading
cause of bloodstream infections, pneumonia, and skin and soft tissue infections (SSTIs) (18).
SSTIs are on the milder side of the severity spectrum of S. aureus infections and include
infections of hair follicles (i.e. furuncles and carbuncles) or the subcutaneous layer (i.e.
cellulitis), which S. aureus can invade upon damage to the epithelial barrier. Severe
infections can arise, however, if the bacteria disseminate to the bloodstream, which can lead
to sepsis, abscesses, infection of muscle or bone, or pneumonia (3). Severe S. aureus
infections

have

historically

been

associated

with

the

hospital

setting,

where

immunosuppression, antibiotic use, surgery, and insertion of medical devices put patients at
risk of invasive disease (3, 19). The global emergence of strains resistant to -lactam
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antibiotics in the 1960s (i.e. methicillin-resistant S. aureus (MRSA)) severely limited
treatment options and gave rise to numerous hospital outbreaks (20, 21). The epidemiology
of S. aureus infections shifted again in the 1990s to early 2000s, when the incidence of SSTIs
in young, healthy individuals increased at an unprecedented level (22). These infections were
traced to new strains of community-associated (CA)-MRSA, referring to the origin of these
infections in individuals lacking the typical health-care associated risks. Although originally
associated with infections with a community onset, CA-MRSA strains, in particular the
USA300 strain, now rival hospital-associated (HA)-MRSA strains in causing nosocomial
MRSA outbreaks (21).
One of the genetic features distinguishing CA-MRSA from HA-MRSA is the staphylococcal
chromosomal cassette mec (SCCmec) element, which carries the mecA gene that confers
resistance to –lactams. The SCCmec element in CA-MRSA is missing non-–lactam
resistance genes and is therefore smaller than that in HA-MRSA (23, 24). CA-MRSA
infections are also associated with the presence of the Panton-Valentine leukocidin (PVL)
(25–27). The USA300 strain can be further distinguished by the acquisition of the argininecatabolic mobile element (ACME), a 30.9 kb pathogenicity island (28). Given its renowned
reputation in the clinic, molecular pathogenesis studies of S. aureus have focused on the
USA300 strain (29, 30).
Several unique features of USA300 are thought to contribute to its overwhelming burden as
the leading cause of SSTIs and severe infections, such as pneumonia and necrotizing fasciitis
(21). With acquisition of the ACME cassette, USA300 gained heightened adaptation to acidic
conditions, like those present on the skin surface (31), and resistance to polyamines, which
increases the persistence of USA300 in abscesses during the healing process (31–33).
Although deletion of the ACME cassette reduces the competitive fitness of USA300 in a
model of bacteremia, no virulence defect is observed for pneumonia or skin abscesses (34,
35). Rather, higher production of notable toxins, including -toxin, the phenol-soluble
modulins (PSMs), and PVL, likely related to the increased expression of their regulators agr
(accessory gene regulatory) and sae (S. aureus exoprotein expression), is believed to
contribute to the hypervirulence of USA300 in comparison to other MRSA strains (29, 30,
36), however, the molecular mechanisms governing these differences remain unknown.
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1.2 The intersection of metabolism and virulence in S. aureus
In general, S. aureus pathogenesis involves three processes; adherence to host tissue, evasion
of host defenses, and replication. Several surface proteins aid in adhesion of S. aureus to
extracellular matrix or host cells, including fibronectin-binding proteins A and B (FnBPA/B),
clumping factors A and B (ClfA/B), and collagen adhesion (Cna) (37). If S. aureus breaches
the surface barriers, it employs its repertoire of virulence factors to circumvent the immune
response. It secretes exotoxins that kill or subvert host cells (leukocidins, hemolysins,
enterotoxins, superantigens, PSMs), produces exoenzymes that destroy host tissue (proteases,
phospholipase C, hyaluronidase), detoxifies antimicrobial peptides and molecules (catalase,
superoxide dismutase, staphyloxanthin), and expresses surface proteins that subvert immune
responses (protein A, Staphylococcal complement inhibitors) (Figure 1.1) (5). The damage of
host tissue also liberates nutrients, such as iron sources, peptides, and lipids that S. aureus
can acquire to support its metabolism. Also fundamental to its growth during infection is the
biosynthesis of nutrients and co-factors (38, 39).
The importance of nutrient scavenging and synthesis for S. aureus virulence is exemplified
by the finding that the majority of genes necessary for infection identified in large-scale
signature-tagged mutagenesis studies fall into the categories of metabolism, transport, and
biosynthesis (38, 39). The most detailed characterization of S. aureus nutrient acquisition is
likely that of the iron acquisitions strategies it employs to overcome the metal withholding
strategies of the host (i.e. nutritional immunity). By encoding, and selectively utilizing,
multiple metal acquisition systems, S. aureus exploits host iron reservoirs to meet the
nutritional requirements of growth (40, 41). The mechanisms for obtaining other important
nutrients, and the regulation of such systems, however, are not well understood.
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Figure 1.1 Staphylococcus aureus virulence factors.
Further linking S. aureus metabolism to virulence is the coordination of virulence factor
expression in response to metabolic cues. Global metabolic regulators not only directly
regulate virulence factor synthesis, but also precede virulence gene regulators in the
hierarchy of transcription, indirectly regulating virulence genes in response to changes in the
environment (42). The expression of virulence genes is controlled by two central regulators;
agr and the staphylococcal accessory regulator (sarA) (43, 44). The agr system is a quorumsensing system that leads to activation of a two component regulatory system upon
accumulation of an autoinducing peptide in the extracellular environment (45). The regulator
of the system activates expression of a regulatory RNA, RNAIII, which upregulates toxin
expression, including hemolysins, PVL, and enterotoxins, and downregulates surface
proteins (46). This regulatory system promotes exotoxin expression in response to high
population cell density, a characteristic of the growth-phase dependent expression of
exoproteins in S. aureus (47). SarA regulates expression of exoproteins and cell wall proteins
directly and indirectly through agr, and although initially considered a DNA-binding
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transcription factor, more likely stabilizes target mRNAs by acting as a histone-like protein
(48–51). Additional regulators of virulence include the sae locus and repressor of toxins (rot)
(52, 53).
To achieve appropriate virulence factor production, the aforementioned regulatory networks
receive input from global transcriptional regulators that respond to environmental cues and
induce metabolic reprogramming to support replication and virulence factor synthesis (42).
Such regulators include redox-responsive regulators (i.e. Rex) (54), oxygen-dependent
regulators (i.e. PerR) (55), metal-dependent regulators (i.e. Fur) (56, 57) and metabolic and
nutrient-responsive regulators (i.e. CcpA) (58). Indeed, recent descriptions of novel
metabolic regulators or metabolic regulons linking carbon metabolism to virulence in S.
aureus continue to add to the complexity of virulence gene regulation (Table 1.1). Notably,
the branched-chain amino acids (BCAAs) are emerging as nutrients at the intersection of
metabolism and virulence in S. aureus due to their role as effectors of CodY, a global
regulator of metabolism and virulence in S. aureus (Table 1.1) (59–61). Obtaining BCAAs is
therefore important not only for the growth of S. aureus, but also for its adaptation to changes
in nutrient availability and the regulation of virulence gene expression. Yet, the strategies S.
aureus employs to obtain BCAAs and the consequence of BCAA limitation on S. aureus
environmental adaptation remain unknown.
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Table 1.1 Regulators of carbon metabolism and virulence in S. aureus
Regulator
CodY

Metabolite sensed
BCAAs, GTP

Select virulence genes
-toxin (hla), hyaludonidase
(hyl), coagulase (coa),
fibronectin-binding protein
(fnBPA), capsule (cap),
polysaccharide intracellular
adhesion (ica), protein A (spa)
Urease, protein A (spa), toxic
shock toxin (tst)

Reference
(59–65)

CcpA

Glucose

CcpE

Citrate

Capsule biosynthesis (capA), toxin (hla), phenol-soluble
modulins- (psm)

(67, 68)

RpiRC

Pentose phosphate
pathway intermediate

Leukocidins, protein A (spa),
capsule (cap), hemolysins,
RNAIII

(69, 70)

(58, 66)
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1.3 Branched-chain amino acids in bacterial physiology
The branched-chain amino acids (BCAAs; isoleucine, leucine, and valine) are small nonpolar amino acids that are hydrophobic in nature due to their branched-alkyl side chains
(Figure 1.2). Leu is one of the most abundant amino acids in proteins and is typically found
in the inner helical core of proteins, as its hydrophobicity is a strong stabilizer of -helical
structures (71). The hydrophobicity of Ile and Val similarly dictates their location in the
hydrophobic core of proteins, however, the substitution of the -carbon with a methyl group
on these amino acids creates bulkiness that restricts the conformation of the main chain and
destabilizes -helical structures. Consequently, Ile and Val are preferentially located in sheets (72, 73).

Figure 1.2 Chemical structure of branched-chain amino acids.
Bacteria synthesize BCAAs through a conserved pathway that is present in Fungi and Plants,
but absent in Mammals. The level of synthesis is dependent on the availability of metabolites
linked to central metabolism, including pyruvate, acetyl-CoA, and -ketobutyrate, which
although not a direct product of central metabolism, is a product of threonine deamination
with threonine being synthesized from aspartate, a product of oxaloacetate transamination
(Figure 1.3). The biosynthetic pathway also provides intermediates for pantothenate
synthesis, which requires -ketoisovalerate, the -keto acids of Val (74), and branched-chain
fatty acid (BCFA) synthesis, the predominant fatty acids (FAs) in membranes of Grampositive bacteria (75). Thus, the importance of BCAAs for bacterial physiology stems from
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their requirement for maintaining high levels of protein synthesis and their integration with
cellular metabolism.

Figure 1.3 Integration of BCAA biosynthesis with cellular metabolism.
Metabolites highlighted in blue are connected to BCAA biosynthesis.

1.3.1

Branched-chain fatty acids

The cytoplasmic membrane of bacteria serves as a barrier to the external environment and is
crucial to the adaptation of organisms to physical changes in the environment, including
temperature, pH, osmolarity and salinity. The FA composition of the membrane determines
its biophysical properties and modification of FAs enable bacteria to adapt to changing
conditions. The predominant FAs in Gram-negative bacteria are short-chain fatty acids
(SCFAs) and in Gram-positive bacteria are BCFAs (75). The synthesis of SCFAs and BCFAs
proceeds through the multi-enzyme fatty acid synthesis (FAS)-II pathway, with acetyl-CoA
as the substrate for SCFA synthesis and branched-chain acyl-CoA as the substrate for BCFA
synthesis (76). Branched-chain acyl-CoA substrates are produced through the transamination
of BCAAs into -keto-acids, which are then decarboxylated by the branched-chain -keto
acid dehydrogenase (BKD) multi-enzyme complex (77). The substrate an organism uses for
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FA synthesis is determined by the substrate specificity of the first enzyme in the FAS-II
pathway, FabH, which catalyzes the condensation of either acetyl-CoA or a branched-chain
acyl-CoA with malonyl-ACP (78, 79). FabF then elongates the product through the repeated
condensation with malonyl-ACP (76). When initiated with branched-chain acyl-CoA
substrates, these reactions produce even-chain anteiso-FAs derived from Ile, even-chain isoFAs derived from Leu and odd-chain iso-FAs derived from Val (Figure 1.4).

Figure 1.4 Synthesis of branched-chain fatty acids from branched-chain amino acids.
The biophysical properties of membranes composed of SCFAs are determined by the degree
of saturation. The FabA and FabB enzymes introduce cis bonds in the acyl chains, which
disrupt order and increase membrane fluidity (80). Homologs of these enzymes are not found
in Gram-positive bacteria, with the exception of Streptococcus pneumoniae and
Enterococcus faecalis (81, 82). Unsaturated FAs are also found in the membrane of Bacillus
subtilis due to the presence of a cold shock-induced desaturase enzyme, which functions
independently of FA synthesis and modifies FAs attached to phospholipids in the membrane
(83).
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The biophysical properties of membranes composed of BCFAs are determined by FA chain
length and the iso:anteiso ratio. These modifications facilitate adaptation to changes in
temperature, pH, salinity, and CO2 (84–86). Of the three BCFAs, anteiso-FAs are the major
determinant of membrane fluidity. The positioning of the methyl group on the acyl chain of
antieso-FAs disrupts close packing of membrane lipids promoting a more fluid membrane.
This property is critical to adaptation to growth at low temperatures, during which the
antieso-FA content is increased (84, 87–89). Both the BKD complex and FabH enzyme
exhibit substrate preference for anteiso-FA synthesis, with the preference of FabH for
anteiso-FA precursors increasing as the temperature decreases (75, 90, 91), emphasizing the
fundamental requirement of anteiso-FAs for homeoviscous adaptation in Gram-positive
bacteria.

1.4 BCAAs as effectors of global transcriptional regulators
To cope with fluctuations in environmental nutrient availability, bacteria undergo metabolic
reprogramming to sustain growth upon nutrient exhaustion. In laboratory growth conditions
this follows a pattern of exponential growth under nutrient rich conditions, followed by a
period of limited/no growth as a result of nutrient depletion. This transition from feast-tofamine coincides with accumulation of ppGpp (92) and is regulated by global transcriptional
regulators; namely the leucine responsive regulatory protein (Lrp) in Gram-negative bacteria
and CodY in Gram-positive bacteria (Figure 1.5) (93, 94). BCAAs directly bind and regulate
the activity of both regulators.

1.4.1

Lrp

Lrp is a highly conserved transcriptional regulator in enteric bacteria that regulates genes
upon transition to stationary phase during bacterial growth (93). Lrp regulates ~10% of the
Escherichia coli genome and either represses or activates target genes in response to Leu,
which can either enhance, antagonize, or have no effect on Lrp activity depending on the
target gene (95). Lrp primarily regulates metabolic gene expression, including glutamate,
glutamine, BCAA, and serine biosynthesis, glycine degradation, and BCAA and oligopeptide
transport, as well as genes involved in pili formation (95). Expression of lrp is induced by
ppGpp (96), a metabolite synthesized from GTP through a reaction that typifies the stringent
response, a response provoked by amino acid starvation (92). The stringent response
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coincides with entrance into stationary phase thereby linking Lrp regulatory activity to
nutrient limitation.

Figure 1.5. Global regulators of stationary phase adaptation in Gram-negative and
Gram-positive bacteria.
Exponential growth is associated with nutrient consumption and subsequently, depletion. As
amino acids become depleted, ppGpp is synthesized from GTP, correlating with the entrance
to stationary phase. As ppGpp accumulates, lrp expression in Gram-negatives is induced. Lrp
binds to Leu and either activates genes involved in amino acid synthesis and transport or
represses genes involved in amino acid catabolism. In Gram-positives, CodY DNA-binding
activity decreases as GTP, as well as BCAAs, are depleted. Target genes involved in amino
acid biosynthesis and transport are induced.

1.4.2

CodY

CodY is a conserved transcriptional regulator in low GC Gram-positive bacteria (i.e.
firmicutes) that senses the metabolic status of the cell and promotes adaptation to nutrient
limitation (97, 98). CodY is activated through direct interaction with BCAAs and GTP (97–
100), with the exception in Lactococcus lactis and Streptococcus pneumoniae, where CodY
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responds to only BCAAs (101–103). In its active state CodY binds to DNA, typically
resulting in transcriptional repression. Approximately half of CodY binding motifs are
upstream or overlapping with transcriptional start sites and interfere with transcription
initiation by either displacing or occluding binding of RNA polymerase or transcriptional
activators (104–107). The remaining CodY binding motifs overlap with the coding region
and block transcriptional elongation (104–107). Less frequently, CodY can directly activate
transcription through an unknown mechanism (108, 109), with the extent of its role as an
activator depending on the species. Thus, in general, CodY target genes are repressed during
rapid growth and become expressed upon nutrient deprivation. CodY regulates metabolic
genes involved in amino acid synthesis, purine biosynthesis, sugar and amino acid transport,
and the Krebs cycle (59, 61, 101, 110, 111), and in some species, it regulates sporulation (97,
112–114) and biofilm formation (115–117).

1.4.2.1 Interaction of CodY with its ligands
The N-terminus of CodY constitutes a GAF domain, a widely distributed domain with roles
in intracellular signaling and transcriptional regulation. The C-terminus is composed of a
helix-turn-helix motif that confers DNA binding activity and is connected to the GAF
domain by a 41 amino acid linker region (118, 119). Ile binds to the GAF domain and
triggers a conformational change that is thought to promote DNA binding activity (120–122).
The binding of GTP to CodY has proved more difficult to discern. Crystallization of GTP
with CodY revealed a GTP binding pocket at the interface of the GAF and the linker region
(119), contradicting initial theories that predicted GTP-binding involved three highly
conserved GTP-binding motifs in the GAF domain (97, 100). GTP binding triggers a
conformation change in the linker region of the protein (123). One group of researchers have
proposed a model of CodY activity where in its liganded state, CodY forms a tetramer that
conceals the DNA-binding domain, preventing DNA binding, and in the absence of ligand it
forms a dimer, exposing the DNA-binding domain (119). Another group has suggested that
the tetramer is not a physiologically relevant conformation, and rather ligand binding causes
conformational changes in the dimer that promote DNA-binding (122). In addition to
conformational changes, autophosphorylation of CodY might contribute to its DNA-binding
activity, although this remains controversial. CodY from Bacillus anthracis has been
observed to autophosphorylate on a serine residue (Ser215) located in the DNA binding
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domain (123). Ser215 is conserved in CodY across Gram-positives (123), has previously been
identified as a site of phosphorylation in B. subtilis (124), and is a critical residue for DNA
binding activity of B. subtilis CodY (118). However, the interaction between CodY and DNA
has previously been shown to be independent of GTP hydrolysis (100), thus further studies
are required to elucidate whether phosphorylation is relevant to CodY DNA-binding activity.

1.4.2.2 CodY binding strength dictates the hierarchy of target
gene expression
CodY binds to a 15-nt binding motif AATTTTCWGAAAATT (105, 125), with a model
emerging where a second binding motif that overlaps by 6 nt confers CodY-dependent
regulation (107, 126). Motifs with nucleotide substitutions that deviate from the consensus
sequence decrease the binding affinity of CodY (105, 107) and in fact, mutating the CodY
motif to a perfect match, which is nonexistent in the B. subtilis genome (107), results in
higher DNA binding activity in the absence of ligands than the binding activity of CodY to
an imperfect sequence in the presence of its ligands (127). The binding strength of the motif
correlates with the extent of repression, such that upon modest decreases in CodY activity,
genes with lower affinity binding motifs are de-repressed and genes with higher affinity
binding motifs remain repressed (127, 128). The strength of the binding motif therefore
dictates when the gene is expressed in the graded de-repression of CodY target genes (128).

1.5 Mechanisms of maintaining intracellular BCAAs
1.5.1

BCAA synthesis

Bacteria maintain intracellular BCAAs through endogenous synthesis or acquisition of
exogenous sources, in the form of free amino acids or peptides. Most bacteria are capable of
de novo BCAA biosynthesis, with the exception of Erysipelothrix rhusiopathiae,
Mycoplasma spp., Ureaplasma spp., Peptostreptococcus anaerobius, Streptococcus
pyogenes, and Streptococcus agalactiae (129). BCAAs are synthesized through a conserved
pathway in Gram-negative and Gram-positive bacteria (Figure 1.6). Ile and Val synthesis
proceed in parallel reactions, apart from the first step. Ile synthesis begins with the
deamination of threonine to form -ketobutyrate, catalyzed by threonine deaminase (IlvA).
Next, acetohydroxy acid synthetase (AHAS) (IlvBN) transfers an active acetyaldehyde from
pyruvate to either -ketobutyrate in the case of Ile or a second pyruvate in the case of Val.
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The resulting acetohydroxy acids are then converted by aceothydroxy acid isomeroreductase
(IlvC) into dihydroxy acids, and then to branched-chain -keto acids by dihydroxy acid
dehydratase (IlvD). Branched-chain amino acid aminotransferase (IlvE) then catalyzes the
transamination of the branched-chain -keto acids to Ile or Val. The pathway for Leu
synthesis proceeds from the branched-chain -keto acid intermediate in Val synthesis. isopropylmalate synthase (LeuA) catalyzes the condensation of -ketoisovalerate with acetyl
coenzyme A to form -isopropylmalate. An isopropylmalate isomerase (LeuBD) then
converts this intermediate into -isopropylamalate, and followed by conversion into ketoisocaproate by -isopropylmalate dehydrogenase (LeuC). The branched-chain keto acid
is then transaminated by IlvE to form Leu. The BCAA biosynthetic genes are typically
organized in at least one operon, depending on the species. In S. aureus the biosynthetic
genes are, with the exception of the ilvE gene, organized in a nine gene operon
(ilvDBNCleuABCDilvA) (Figure 1.6).
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Figure 1.6 Biosynthetic pathway for isoleucine, leucine, and valine and organization of
the biosynthetic operon in S. aureus.

1.5.1.1 Transcriptional regulation of BCAA biosynthetic operons
The most detailed descriptions of the regulation of BCAA biosynthesis come from studies in
E. coli and B. subtilis. The genes for BCAA biosynthesis in E. coli are organized into two
operons; ilvGMEDA and leuABCD. In addition to the ilvGM AHAS enzyme encoded by the
ilv operon, E. coli encodes two additional AHAS isoenzymes, encoded by ilvIH, and ilvBN.
Regulation of BCAA biosynthesis in E. coli is primarily mediated by transcriptional
attenuation. Transcriptional attenuation involves an open reading frame upstream of the gene
that is rich in regulatory codons. Depletion of tRNA corresponding to the regulatory codons
causes the ribosome to stall. The stalling of the ribosome allows base-pairing of the leader
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mRNA to form an anti-terminator stem loop. This base-pairing prevents formation of the
terminator hairpin and results in transcriptional read-through (Figure 1.7). High levels of the
appropriate tRNA allow the ribosome to continue translation, blocking formation of the
antiterminator structure and promoting formation of the terminator hairpin (Figure 1.7). In
this way, attenuation couples transcription of the biosynthetic operon with the availability of
amino acids. Indeed, the ilvGMEDA operon is preceded by a 32 aa peptide that contains 15
BCAAs (130, 131), ilvBN is preceded by a 32 aa peptide with 11 BCAAs (132) and the
leuABCD operon is preceded by a 28 aa peptide containing 4 Leu (133). Attenuation is also
the primary mechanism of regulating the leu operon in Salmonella typhimurium (134, 135)
and putative leader peptides and terminator hairpins are found upstream of BCAA
biosynthesis genes across various Gram-negative species (136), suggesting that attenuation is
a

conserved

mechanism

of

regulating

BCAA

biosynthesis.

Figure 1.7 Transcriptional attenuation of BCAA biosynthesis.
In conditions where levels of Leu and Val are limited, the corresponding tRNA is not
available for translation of the leader peptide that is rich in Leu (L) and Val (V). The
ribosome stalls on the mRNA, promoting formation of the anti-terminator stem loop forms.
Transcription proceeds. In conditions where Leu and Val are in excess, the corresponding
tRNA is available for translation of the leader peptide. The ribosome proceeds along the
mRNA, promoting formation of the terminator stem loop. Transcription does not proceed.

18

The biosynthetic genes are also regulated by Lrp. In the absence of Leu, binding of Lrp to the
ilvIH promoter activates transcription and binding to the ilvG promoter represses
transcription (137–139).
The genes for BCAA biosynthesis in B. subtilis, are encoded by the ilvBHCleuABCD operon
and ilvA, ilvD, and ybgE. Regulation of the ilv-leu operon in B. subtilis involves multiple
global regulators that coordinate expression of the operon in response to carbon, nitrogen,
and amino acid availability (Figure 1.8) (140). The operon is positively regulated by the
carbon catabolite protein A (CcpA) (140, 141), a global transcriptional regulator that
regulates carbon utilization in response to a preferred carbon source (142). CcpA activates or
represses its target genes by binding to the catabolite-responsive element (cre), a cisregulatory element in the promoter region of the target gene, when in complex with the
phosphorylated form of the Hpr protein (143). Hpr is a component of the phosphoenolpyruvate-dependent phosphotransferase transporter system that is phosphorylated by HprK, a
kinase that is activated by fructose 1,6-bisphosphate (144). Thus, CcpA activates
transcription when there is sufficient carbon for BCAA biosynthesis. When ccpA is mutated,
the BCAAs are not synthesized (145).

Figure 1.8 Regulation of the ilvB promoter in Bacillus subtilis. Binding sites for
transcriptional regulators of the ilv-leu operon in B. subtilis are indicated relative to the
promoter and transcriptional start site of ilvB. TnrA binds to the TnrA Box and represses
transcription in the presence of nitrogen. CodY binds to four binding sites and represses
transcription in the presence of BCAAs and GTP. CcpA binds to the catabolite response
element (cre) and activates transcription in the presence of a preferred carbon source (i.e.
glucose).
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The positive regulation of ilvB by CcpA is antagonized by either TnrA or CodY (146). TnrA
binds to its target sequence in response to nitrogen limitation and either represses or activates
gene involved in nitrogen metabolism (147). Binding of TnrA to the ilvB promoter represses
transcription, limiting BCAA biosynthesis when nitrogen is scarce (148). CodY represses
ilvB transcription when cells are replete of GTP and BCAAs (99, 110), allowing for
conservation of carbon and nitrogen when exogenous BCAA sources are present. A highaffinity CodY binding site proximal to the cre allows CodY to directly compete with CcpA
binding to the ilvB promoter (140, 141, 146). The mechanism by which TnrA prevents CcpA
activation is less clear, as the TnrA box is upstream of the cre and therefore does not interfere
with CcpA binding. One model proposes that when TnrA binds to DNA it forms a complex
with CcpA/P-Hpk and induces DNA bending that prevents RNA polymerase from initiating
transcription through steric hindrance (146). Additional fine-turning of ilv-leu expression is
mediated by a Leu-responsive T-box riboswitch (140, 149–151), as well as mRNA
processing (152).
CodY-dependent repression of BCAA biosynthesis is common across Gram-positives,
including S. aureus (59, 61, 102, 153–155), whereas TnrA homologs are less conserved
(156), suggesting that nitrogen levels might not influence BCAA biosynthesis in other
species. Additionally, the T-box mechanism of ilv-leu regulation has not been observed in
any other Gram-positives, and therefore appears to be unique to B. subtilis. Rather,
bioinformatics analysis of the leader sequence of the BCAA biosynthetic genes in L. lactis
(157), Corenybacterium glutamicum (158, 159), and Streptococcus spp. (160) have revealed
BCAA-rich peptides and terminator hairpins consistent with attenuation. In S. aureus, an
additional regulatory mechanism governing BCAA biosynthesis has been described
involving repression by the essential Gcp/YeaZ complex (161, 162). Gcp and YeaZ are
homologous to proteins in E. coli that function as a complex to synthesize t6A, a
modification of tRNA that strengthens the A-U codon:anti-codon interaction on the ribosome
(163). Consistent with this, reducing levels of Gcp in S. aureus results in a decrease in t6A
modification (161). Interestingly, YeaZ binds upstream of the ilv-leu operon, suggesting
possible direct repression of the operon (162). The conditions that regulate its binding are
currently unknown.
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1.5.1.2 Allosteric regulation of biosynthetic enzymes
In addition to transcriptional regulation, the biosynthetic enzymes involved in BCAA
biosynthesis are subject to feedback inhibition and activation. Firstly, threonine deaminase
(TD), which catalyzes the first step in Ile synthesis, is inhibited by Ile and activated by Val.
TD is a pyridoxal phosphate-dependent enzyme that contains an N-terminal catalytic domain
and a C-terminal regulatory domain. The C-terminal regulatory domain contains one or two
ACT-like sub-domains. The E. coli TD enzyme, which contains two ACT-like sub-domains,
is inhibited by Ile and activated by Val (164–166). The B. subtilis TD enzyme, which
contains one ACT-like sub-domain, is inhibited by Ile and it is proposed that Val activates
TD in the presence of Ile and inhibits TD at high concentrations (167). Secondly, the AHAS
enzyme, which catalyzes the condensation of pyruvate with either -ketobutyrate or pyruvate
for Ile and Val synthesis, respectively, is also subject to feedback inhibition by BCAAs. E.
coli encodes three AHAS isoenzymes; AHAS-I (IlvBN), which is inhibited by Val, AHASIII (IlvIH) which is inhibited by all three BCAAs, and AHAS-II (IlvGM), which is
insensitive to feedback inhibition by BCAAs (168). The redundancy in AHAS isoenzymes
presumably allows E. coli to synthesize Ile even in the presence of the other BCAAs. Lastly,
-Isopropylmalate synthetase, which catalyzes the first step in Leu synthesis is inhibited by
Leu (169).
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1.5.2

BCAA transport

Repression of BCAA biosynthesis when intracellular levels are sufficient to support growth
allows bacteria to conserve carbon and nitrogen, and instead rely on acquisition of exogenous
sources of BCAAs to support metabolism. Active transporters specific to BCAAs are
common across bacteria and require either ATP or the proton motive force to import BCAAs.
BCAA transporters in Gram-negatives (Table 1.2), first described in E. coli, include the highaffinity LIV-I system and the low-affinity LIV-II and LIV-III systems (Figure 1.9).

Figure 1.9 Mechanisms of BCAA transport in Gram-negative bacteria.
LIV-I is an ATP-Binding Cassette (ABC) transporter encoded by livJKHMGF (170). Two
substrate binding proteins mediate BCAA transport through this system; LIV-B (livJ), which
can bind all three BCAAs, and LS-B (livK), which is Leu specific (171, 172). LIV-II, also
known as BrnQ, is a permease with 12 transmembrane helices and belongs to the Major
Facilitator Superfamily (MFS). LIV-III is a permease homologous to LIV-II, with transport
activity that is obviated only in a LIV-II deficient background in Salmonella typhimurium
and Pseudomonas aeruginosa (173, 174). LIV-II and LIV-III use energy from the proton
motive force to couple BCAA transport with Na+ across an energy gradient (175). An
additional MSF transporter specific to Ile transport and unique to Francisella tulaneris has
12 transmembrane helices and belongs to the phagosomal nutrient transport family of MSF
transporters identified in Legionella pneumophilia (176, 177).
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Table 1.2 BCAA transporters in Gram-negative bacteria.
Organism
Chlamydia trachomatis
Escherichia coli

Francisella tularensis
Pseudomonas aeruginosa

Salmonella typhimurium

Transporter

Energy
Source
LIV-II (brnQ)
PMF
LIV-I (livKHMGF) ATP
LIV-I (livJHMGF) ATP
LIV-II (brnQ)
PMF
ileP
PMF

Specificity

Reference

ILV
Leu
ILV
ILV
I

(176)
(170–172,
178)

LIV-I
LIV-II (braB)
LIV-III (braZ)
LIV-I
LIV-II (brnQ)
LIV-II

ILV
ILV
ILV
ILV
ILV
ILV

(180–184)

ATP
PMF
PMF
ATP
PMF
PMF

(179)

(173,
188)

185–

BrnQ also functions as a BCAA transporter in Gram-positive bacteria, along with a second
nonhomologous permease, BcaP (Table 1.3). L. lactis acquires BCAAs via both BcaP and
BrnQ, with BcaP playing a more predominant role (189, 190). Similarly, BcaP is the
predominant transporter in B. subtilis, with two additional transporters, BrnQ and BraB (a
BrnQ homolog) contributing to Ile and Val uptake, and an unidentified transporter
contributing to Leu uptake (191). A LIV-I system with a substrate binding protein able to
bind BCAAs has been described in S. pneumoniae, although no transport function has yet
been ascribed to this system (192). BrnQ also directs BCAA transport in Lactobacillus
delbrücki and C. glutamicum (193, 194). Although brnQ homologs exist in S. aureus, the
transport functions of these gene products have not been formally tested.
Table 1.3 BCAA transporters in Gram-positive bacteria.
Organism

Transporter

Bacillus subtilis

bcaP
braB
brnQ
brnQ

Corynebacterium
glutamicum
Lactobacillus delbrückii
Lactococcus lactis

brnQ
brnQ
bcaP
Streptococcus pneumoniae livAJHMGF

Energy
Source
PMF
PMF
PMF
PMF

Specificity

Reference

ILV
ILV
ILV
ILV

(191)

PMF
PMF
PMF
ATP

ILV
ILV
ILV
ILV

(193)
(189, 190)

(194)

(192)
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1.6 Nutritional importance of BCAAs for pathogen growth in
vivo
Both BCAA biosynthesis and transport have been linked to promoting the virulence of
pathogens in host environments, most of which are likely limited for BCAAs. Metabolomics
studies indicate that human nasal secretions contain Leu concentrations in the range of 130287 M, Val in the range of 13-156 M, and undetected levels of Ile (195). Human serum
contains Leu, Val and Ile at approximate concentrations of 98 M, 212 M, and 60 M,
respectively (196). Indeed, pathogens exploit these sources, as large-scale mutant screens
have identified BCAA transporters as important genes for the virulence of Yersinia pestis, S.
aureus, and S. pneumoniae (192, 197–199). Given the redundancy in BCAA transporters in
any given organism (Table 1.2, Table 1.3), single gene mutant screens are likely to
underestimate the requirement of BCAA transport for virulence.
The intracellular environment is also presumably limited for BCAAs, as intracellular
pathogens up-regulate BCAA biosynthetic genes within host cells (200). To sustain
replication in this host niche, intracellular pathogens, including Burkholderia pseudomallei,
Mycobacterium bovis, Mycobacterium tuberculosis, and Listeria monocytogenes must
synthesize BCAAs (201–205). Despite the limiting concentrations of BCAAs in the host
cytosol, F. tularensis is able to exploit this source and requires the Ile transporter IleP for
optimal intracellular replication and infection in vivo (176).
If deprived for BCAAs, pathogens not only face challenges in supporting protein synthesis,
but also in maintaining the appropriate BCFA content to protect against host defenses that
target the bacterial membrane. A role for BCFA synthesis in promoting resistance to host
defenses is best highlighted in L. monocytogenes, where BCFAs comprise ~90% of the
membrane (84, 87). BCFA deficient strains have increased susceptibility to antimicrobial
peptide killing, lysozyme digestion, and decreased production of the virulence factor
listeriolysin O (206), all of which likely contribute to the decreased intracellular growth and
virulence of a strain deficient of BCFAs (206, 207). In S. aureus, BCFAs comprise ~65% of
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the membrane and a BCFA deficient strain exhibits reduced adherence to host cells and is
attenuated in vivo (208).
One challenge to understanding the importance of BCFA content to growth in vivo is the
effect that the growth environment has on fatty acid content (209). For example, some
pathogens, such as S. aureus, are able to incorporate exogenous host-derived short-chain
unsaturated fatty acids (SCUFAs) into the membrane (210). When provided a source of host
FAs (i.e. human serum), SCUFAs comprise 25-50% of the S. aureus membrane (209, 211),
reducing the requirement for endogenously synthesized BCFAs (211). The extent to which
exogenous host-derived FAs can replace endogenously synthesized FAs in other pathogens
requires further investigation.

1.7 Regulatory importance of BCAAs for virulence gene
expression in vivo
CodY is recognized as an important regulator of the intersection between metabolism and
virulence in a number of Gram-positive pathogens, including Bacillus anthracis (212, 213),
Bacillus cereus (115, 155, 214, 215), Clostridium difficile (112, 154, 216), Clostridium
perfringens (113, 217), L. monocytogenes (109, 111, 153, 200), S. aureus (59–62, 64, 65), S.
pneumoniae (102), and Streptococcus pyogenes (117, 218–220). CodY regulates between 50300 genes in these pathogens, and although traditionally considered a transcriptional
repressor, an unexpected role for CodY in virulence gene activation has emerged (Table 1.4).
Since GTP and BCAA availability determines the extent of CodY activity, their intracellular
and extracellular levels represent an important signal for the adaptation of pathogens to host
niches. These levels presumably fluctuate considerably as a consequence of nutritional
demand of the pathogen and environmental availability, both of which are difficult to discern
in the various host niches that pathogens infect. One approach to resolve this is to mutate the
mechanisms for acquiring or synthesizing GTP and BCAAs. This approach has proved
insightful to understanding the role of GTP concentrations in regulating virulence gene
expression (63, 153, 221). Modulation of intracellular BCAA concentrations, however, is
challenging given the redundancy in acquisition pathways. Rather, studies using CodY
protein variants that mimic graded BCAA nutrient deprivation or involving limitation of
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exogenous sources of BCAAs have generated important insight into the coordination of
target gene regulation in response to decreasing BCAA concentrations (60, 111, 200).
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Table 1.4 CodY regulation of virulence in Gram-positive pathogens
Organism
Staphylococcus
aureus

Streptococcus
pneumoniae

Bacillus
anthracis

Phenotype of codY
mutant in vivo
Hypervirulent in
skin abscess and
pneumonia. No
effect on systemic
infection.

Reduced
colonization. No
effect on systemic
infection.
Attenuated
virulence

Clostridium
perfringens
(Type D)
(Type A)

ND

Bacillus cereus
(F4810/72)

Attenuated
virulence

Clostridium
difficile

ND

Listeria
monocytogenes

Attenuated
virulence

Streptococcus
pyogenes

ND

Notable virulence gene
regulation
ID repression of deltatoxin/RNAIII via repression of
agr activator, D repression of
biofilm synthesis (icaADBC), toxin (hla), hyaluronidase
(hysA), Panton-Valentine
leukocidin (lukSF-PV)
D activation of adhesion protein
choline-binding protein (pcpA)

Reference

ID activation of anthrax toxin
components (cya, lef, pagA);
ID/D activation of iron
scavenging systems
D&ID activation of epsilon
toxin (ETX); Repression of
sporulation
D/ID activation of sporulation
and enterotoxin (CPE)
ID activation of cytotoxin
(cytK), enterotoxin (nhe), and
hemolysin (hbl) via D activation
of regulator plcR; D repression
of cereulide (cesPTABCD) and
inhibitor metalloprotease 1
(inhA1)
ID repression of toxin A (tcdA)
and B (tcdB) via D repression of
tcdR
ID activation of listeriolysin O
(hyl) via D activation of
regulator prfA; D activation of
flagellar biosynthesis and ActA
ID activation of surface proteins
via ID/D activation of regulator
mga; ID/D activation of
regulators fasX and pel/sagA

(212, 213)

(59, 62,
221, 222)

(102)

(113, 217)
(223)

(215)

(216)

(111, 200)

(218, 219)

ND = Not determined; ID = indirect regulation; D = direct regulation; ID/D = unknown
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1.7.1

Implications of GTP depletion on CodY regulation

Bacteria obtain GTP through biosynthesis or transport, and further regulate intracellular
pools by conversion of GTP to (p)ppGpp in response to amino acid starvation (i.e. the
stringent response) (92). Two classes of enzymes are involved in the stringent response;
monofunctional synthases that synthesize (p)ppGpp from GTP, and bifunctional enzymes
that can synthesize (p)ppGpp as well as hydrolyze the molecule back to GDP or GTP (224).
In addition to consuming GTP for its synthesis, (p)ppGpp depletes GTP levels by inhibiting
an enzyme required for GTP synthesis (225). Of these mechanisms, the synthesis of
(p)ppGpp from GTP represents an important link between GTP levels and CodY virulence in
Gram-positive pathogens (63, 221).
Mutation of the synthase function of the bifunctional enzyme in S. aureus (RSH) and L.
monocytogenes (RelA) has two consequences on the cell; i. the inability to accumulate
(p)ppGpp leads to loss of stringent response gene induction, and ii. the high level of GTP
leads to continued repression of CodY target genes (63, 153, 221, 226). Without derepression of CodY target genes, the synthase mutants of both pathogens are attenuated in
vivo, a phenotype that is reversed upon subsequent mutation of codY in this background (153,
221). Although CodY-regulated products in S. aureus include virulence factors, such as
capsule genes and the agr locus, amino acid starvation does not induce these targets (63).
These data suggest that the importance of amino acid starvation for promoting virulence is
related to CodY-dependent metabolic reprogramming, and not virulence factor production.
They further reveal that depletion of just one CodY effector is not sufficient to completely
relieve repression of all CodY target genes.

1.7.2

Implications of BCAA depletion on CodY regulation

Emerging evidence indicates that the consequence of BCAA depletion on virulence varies by
pathogen. In the more traditional case, CodY acts as a negative regulator of virulence genes
in S. aureus. CodY regulates approximately 5% of the S. aureus genome, with the majority
of its targets (85%) subject to repression by CodY (59, 61). These targets include virulence
genes, such as the capsule genes, -hemolysin and adhesion proteins, as well as regulators of
virulence gene expression, including the agr locus and saeRS two-component system (65).
Most of the virulence genes are directly repressed by CodY, whereas others, including the
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capsule genes and hemolysins, are indirectly activated by agr (59, 61). The genes activated
by CodY, which fall into the categories of nucleotide transport/metabolism and adhesion
proteins, do not have a CodY binding sequence, suggesting an indirect mechanism of
regulation (59). The coordination of virulence gene expression with the environment is
crucial for S. aureus to limit unwanted host-damage as exemplified by the hypervirulence of
a codY mutant in a skin abscess and pneumonia model of infection (62). To ensure the
appropriate expression of virulence genes, the CodY regulon is expressed as a hierarchy that
depends on the extent of CodY activation, and therefore nutrient availability (60). This
hierarchy was determined by analyzing the transcriptome of S. aureus strains expressing
mutated CodY proteins that mimic various levels of Ile deprivation (60). This approach
revealed that the graded response prioritizes amino acid and peptide transport over synthesis
upon modest nutrient limitation, and reserves hydrolytic enzyme and toxins production for
more severe nutrient limitation (Figure 1.10) (60). Also within this spectrum are other
virulence gene regulators, including the agr and sae locus, that together form a regulatory
cascade that integrates several environmental cues, such as growth phase and host defenses
(60, 227). Together, the graded response and regulatory cascade allow S. aureus to maximize
nutrient acquisition while limiting host toxicity (60).

Figure 1.10 CodY regulation of virulence genes in Staphylococcus aureus and Listeria
monocytogenes.
CodY target genes are either activated or repressed by CodY depending on BCAA
availability. Black lines indicate genes that are repressed by CodY. Red lines indicate genes
that are activated by CodY. The thickness of the line corresponds to the relative proportion of
genes in that category.
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Limitation of BCAAs in L. monocytogenes produces a much more complex response. CodY
directly or indirectly regulates approximately 14% of genes in L. monocytogenes, with a
much greater proportion of genes requiring CodY for activation (111). In nutrient-rich
growth medium, approximately 66% of target genes are up-regulated in a codY mutant, and
in BCAA-limited growth medium approximately 70% of target genes are up-regulated (111).
When BCAAs are present in excess, genes primarily involved in nutrient metabolism and
transport, stress responses, and some virulence factors are repressed. Under these same
conditions, other metabolic genes, including arginine biosynthesis, are activated by CodY.
When BCAAs are limited, amino acid and iron transport genes are repressed, whereas prfA,
the global virulence gene regulator in L. monocytogenes, as well as its downstream genes, are
activated by CodY (Figure 1.10) (109, 111). Notably, CodY is a direct activator of prfA and
binds within its coding region specifically under BCAA limiting conditions (109). This
results in activation of PrfA-regulated virulence factors, including listeriolysin O and the
surface protein ActA, which are important for intracellular replication and cell to cell spread,
respectively (200, 228, 229). CodY also directly activates flagellar biosynthesis genes.
Consequently, a codY mutant is impaired in motility, intracellular replication, and survival in
vivo (109, 111). The mechanism of prfA activation remains uncertain, as it does not appear to
involve BCAA-binding and it is unclear how binding of CodY within a coding region would
activate transcription (109). These data reveal how the CodY regulatory activity in response
to BCAA depletion in L. monocytogenes contrasts the predominant negative regulatory
activity observed in other organisms.
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1.8 Rationale and Hypothesis
S. aureus is a significant human pathogen that exhibits extraordinary replicative capacity in
diverse host niches by withstanding changes in host defenses, temperature, pH, oxidative
stress, osmotic stress and nutrient availability. How it obtains the nutrients it requires for
growth in such hostile environments and what environmental cues it responds to, to regulate
its adaptation to these environments are not fully understood. The BCAAs are of interest to
study, as they provide the opportunity to investigate both of these aspects of S. aureus
virulence due to their physiological role (i.e. protein synthesis and FA synthesis) and their
regulatory role (i.e. via CodY). Yet, there are no detailed descriptions of the mechanisms S.
aureus uses to obtain BCAAs to support these functions. Therefore, the objective of this
thesis was to characterize how S. aureus obtains BCAAs and to investigate the consequences
of modulating intracellular BCAAs on S. aureus physiology and virulence.
S. aureus encodes an intact BCAA biosynthetic operon, however, it has been reported as
auxotrophic for Leu and Val (230, 231). Therefore, in Chapters 2 and 3, I, along with my
colleagues, investigate the hypothesis that BCAA acquisition via specialized transporters
is required for S. aureus physiology and virulence. In Chapter 4, my colleagues and I
sought to resolve the conundrum of why the intact BCAA biosynthetic operon does not
support de novo BCAA biosynthesis in the absence of an exogenous source. We
hypothesized that selection for S. aureus mutants able to grow in the absence of
exogenous BCAAs would enable identification of novel regulators of the biosynthetic
operon in S. aureus.
An improved understanding of the metabolic requirements of S. aureus infection and the role
that metabolic cues play in regulating virulence could reveal pathways to target with
therapeutics to help reduce the infectious burden of this pathogen.
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Chapter 2

2

The role of BrnQ transporters in BCAA acquisition

2.1 Introduction
Staphylococcus aureus is a highly successful human pathogen that succeeds at infecting
virtually every body site, causing skin, soft tissue, respiratory, bone, joint and endovascular
infections (1). Maintenance of metabolic homeostasis is important for its infection process, as
the majority of genes necessary for infection identified in large-scale signature-tagged
mutagenesis (STM) screens fall into the categories of metabolism, transport and biosynthesis
(2, 3). Acquisition of host-derived nutrients, specifically amino acids, appears to be an
important mechanism of meeting nutritional needs, as a large proportion of attenuated STM
strains contain mutations in amino acid transporters (3).
Amino acid transporters are ubiquitous in bacteria and are typically selective for transporting
either one amino acid or several amino acids with related structures (4). The branched-chain
amino acids (BCAAs; Ile, Leu, Val) are hydrophobic amino acids typically found in the core
of globular proteins or in the trans-membrane domain of cell surface proteins (5). The
transport mechanisms described for acquisition of the BCAAs in bacteria include secondary
transporters belonging to the Leu, Ile, Val:cation symporter (LIVCS) family (e.g. BrnQ,
BraB, BraZ, BcaP) (4, 6–9) and the LIV-I ABC transporter (10–13). With the exception of an
ABC transporter in Streptococcus pneumoniae (14), secondary transport, which couples the
movement of an ion, usually Na+ or H+, down its concentration gradient with the movement
of another molecule against its concentration gradient, is the primary means of BCAA
acquisition in Gram-positive bacteria.
S. aureus necessitates BCAA transport for growth, as it exhibits an auxotrophic phenotype
for Leu and Val, despite possessing the genes necessary for their biosynthesis (15–17). The
mechanisms of BCAA acquisition, however, have not been described in this species.
Strategies to maintain intracellular levels of BCAAs are of additional interest in S. aureus
since the BCAAs also act as co-repressors of the global transcriptional regulator CodY (18–
20). CodY, a highly-conserved regulatory protein in low G+C Gram-positive bacteria, uses
binding of BCAAs and GTP to sense the metabolic status of the cell, the downstream effect
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of this being the adaptation of the cell to nutrient limitation (21, 22). CodY is activated
through direct interaction with the BCAAs as well as GTP (18–20, 23) and, in its active state,
represses transcription of upwards of 100 genes (17, 24, 25). Depletion of BCAAs and GTP
results in de-repression of CodY target genes, the products of which are involved in a range
of cellular processes depending on the species, including sporulation (23), biofilm formation
(26, 27), protein degradation and utilization (22), and amino acid metabolism and transport
(17, 24). More recently, CodY has emerged as a regulator of virulence in S. aureus (28–30),
implicating CodY as an important link between the nutrient status of the cell and virulence.
Recent characterization of the CodY regulon in S. aureus revealed amino acid metabolism
and transport genes as a major class of CodY targets, including the brnQ1 and brnQ2 BCAA
transporter genes (17, 24). We therefore hypothesized that BCAA transport is involved in
adaptation to nutrient limitation, and might also serve as an important mechanism to maintain
intracellular pools of BCAAs that affect CodY activity and, in turn, regulate virulence of S.
aureus. Despite the potential importance of BCAA transport in regulating virulence in S.
aureus, no BCAA transporter has, as yet, been functionally characterized for a role in BCAA
uptake. In this study we sought to characterize the transport function of the brnQ genes in S.
aureus and investigate their role in nutrient acquisition and virulence in a murine model of S.
aureus infection.
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2.2 Materials and Methods
2.2.1

Bacterial strains and growth conditions

Bacterial strains used in this study are described in Table 2.1. MRSA isolate pulsed-field gel
electrophoresis type USA300 LAC that has been cured of the erythromycin resistance
plasmid was used in all experiments as the wild type (WT) strain. S. aureus strains were
grown either in tryptic soy broth (TSB) or in a chemically-defined medium (CDM),
described previously (31). Complete CDM was composed of the following (final
concentrations in μM): alanine (672), arginine (287), aspartic acid (684), cysteine (166),
glutamic acid (680), glycine (670), histidine (129), isoleucine (228), leucine (684), lysine
(342), methionine (20), phenylalanine (240), proline (690), serine (285) threonine (260),
tryptophan (50), tyrosine (275), valine (684), thiamine (56), nicotinic acid (10), biotin (0.04),
pantothenic acid (2.3), MgCl2 (1000), CaCl2 (100), monopotassium phosphate (40000),
dipotassium phosphate (14700), sodium citrate dehydrate (1400), magnesium sulfate (400),
ammonium sulfate (7600), glucose (27753). The concentrations of individual amino acids
were modified in some experiments as indicated. Where required, chloramphenicol (10 μg
mL-1), erythromycin (3 μg mL-1) and tetracycline (4 μg mL-1) were added to growth medium.
All growth curves were performed at 37˚C with shaking using a flask:volume ratio of at least
7:1. For growth curves performed in TSB medium, S. aureus strains were pre-grown to midexponential phase in TSB and sub-cultured into fresh TSB to a starting OD600 equivalent of
0.0025. For growth curves performed in CDM, S. aureus strains were pre-grown to midexponential phase in complete CDM and sub-cultured into fresh CDM to a starting OD600
equivalent of 0.0025; as indicated in the Results section, either complete CDM or CDM with
altered concentrations of amino acids was used. The optical densities of the cultures were
measured until stationary phase was reached, or until desired time points were reached.
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Table 2.1 Bacterial strains and plasmids used in this study
Strain/Plasmid

Description a

Source or
reference

USA300 LAC cured of antibiotic resistance
plasmid
rK- mK+ ; capable of accepting foreign DNA
Prophage-cured laboratory strain
WT clinical isolate
Newman brnQ3::Tet, TetR
USA300 ΔbrnQ1 (SAUSA300_0188)
USA300 ΔbrnQ2 (SAUSA300_0306)
USA300 brnQ3::Tet; TetR (SAUSA300_1300)
USA300 ΔbrnQ1 ΔbrnQ2 brnQ3::Tet; TetR
USA300 brnQ2::ΦNΣ
USA300 codY::ΦNΣ

This study

S. aureus
USA300
RN4220
RN6390
Newman
H2324
H2568
H2563
H2578
H2589
H2994
H3001

(32)
(33)
(34)
This study
This study
This study
This study
This study
This study
This study

E.coli
DH5α

F- ϕ80dlacZΔM15 recA1 endA1 gyrA96 thi-1
hsdR17 (rK− mK-) supE44 relA1 deoR Δ(lacZYAargF)U169phoA

Promega

E. coli/Staphylococcus shuttle vector allowing
allelic replacement in S. aureus
Antibiotic resistant cassette
Temperature-sensitive E. coli/S. aureus shuttle
vector
Anhydrotetracycline-inducible expression vector;
Apr in E. coli; Cmr in S. aureus
pRMC2 containing brnQ1; Cmr
pRMC2 containing brnQ2; Cmr
pRMC2 containing brnQ3; Cmr

(35, 36)

Plasmids
pKOR1
pDG1513
pMAD
pRMC2
pSO1
pSO2
pSO3
a

(37)
(38)
(36)
This study
This study
This study

Abbreviations: Tetr, Cmr and Apr designate resistance to tetracycline, chloramphenicol and
ampicillin, respectively.
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2.2.2

Mutagenesis of brnQ genes and complementation of mutants.

Clean deletions of brnQ1 and brnQ2 genes were constructed using the pKOR-1 plasmid as
described previously (35). Primer sequences were based on the published USA300 FPR3757
genome and are displayed in Table 2.2 (39). Briefly, sequences flanking the brnQ locus were
PCR-amplified and a PCR amplicon of the joined DNA fragments was recombined into the
temperature-sensitive vector pKOR1 using BP clonase reaction (Invitrogen), resulting in the
pKOR-1ΔbrnQ1 and pKOR-1ΔbrnQ2 plasmids. To overcome the restriction barrier of S.
aureus, these plasmids were first passed through the restriction-defective S. aureus strain
RN4220, before electroporation into strain USA300. Precise in-frame allelic replacement of
the brnQ genes was established by a two-step process of temperature shifting and antisense
counter-selection and confirmed by PCR and DNA sequencing. A schematic representation
of the pKOR deletion strategy is depicted in Figure 2.1. The brnQ3::Tet knockout allele
consisted of a tetracycline resistance cassette, excised from plasmid pDG1513 with
restriction enzyme PstI, flanked by DNA sequences homologous to regions upstream and
downstream of brnQ3 – leaving the first 69 bp of the start of the gene and the last 34 bp of
the gene. The knockout allele was cloned to the temperature-sensitive E. coli/S. aureus
shuttle vector pMAD, and then passaged through S. aureus RN4220 at permissive
temperatures prior to being transduced using phage 80α into S. aureus RN6390.
Recombinant RN6390 was cultured at 30˚C to mid-log phase before incubation temperature
was shifted to 42˚C. The bacteria were further incubated for 16 hr before being plated onto
TSA containing tetracycline. Colonies were screened for sensitivity to erythromycin, which
indicates loss of the pMAD backbone DNA after integration of the knockout allele into the S.
aureus chromosome via double homologous recombination. The brnQ3::Tc mutation was
confirmed by PCR and mobilized to S. aureus USA300 by transduction using phage 80α.
Transposon insertions in the brnQ2 and codY genes were identified in the Nebraska
Transposon Mutant Library with strain IDs of NE605 and NE1555, respectively. The
transposons were transduced into our laboratory strain of USA300 using phage 80α and
insertion was confirmed by PCR. For complementation vectors, the brnQ genes, including
their native promoters, were cloned into the shuttle vector pRMC2 Table 1.2 (36).
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Figure 2.1 Strategy for markerless gene deletion in S. aureus.
The pKOR vector replicates extra-chromosomally at 30˚C and integrates at 42˚C. Regions
upstream and downstream of the gene of interest, approximately 800-1000 bp in size, are
amplified and cloned into pKOR. Cells are grown at 42˚C to promote chromosomal
integration via homologous recombination, and then subsequently grown at 30˚C to promote
excision. The plasmid is lost via negative selection upon induction of anti-sense RNA, which
silences an essential gene in S. aureus.
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Table 2.2 Oligonucleotide primers used for mutagenesis, cloning, and RT-PCR
Oligonucleotides a
brnQ1 5’F
brnQ1 5’R

GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGACCTGCAAGA
AGGTATTC
GGGCGTAAGTTAAGAACGA
Generation of 5’ arm for deletion of S. aureus brnQ1

brnQ1 3’F
brnQ1 3’R

/5Phos/AAGGAGGGAGACCGATGAAT
GGGGACCACTTTGTACAAGAAAGCTGGGTTGGCTAAAGGGT
TACCACCA
Generation of 3’ arm for deletion of S. aureus brnQ1

brnQ2 5’F

GGGGACAAGTTTGTACAAAAAAGCAGGCTGCGCCATAGACA
GGTTTAGC
TGGAAATACGTTGGAGCGTTG
Generation of 5’ arm for deletion of S. aureus brnQ2

brnQ2 5’R
brnQ2 3’F
brnQ2 3’R

/5Phos/ACCCATCGTTACTAGGCTTT
GGGGACCACTTTGTACAAGAAAGCTGGGTTAAAAGCCGCAG
CGATATTC
Generation of 3’ arm for deletion of S. aureus brnQ2

brnQ3 5’F- SalI
brnQ3 5’R- PstI

TTGTCGACGATTGAACGAGAACAACGAGATGC
TTCTGCAGGCGTAAACCCAATGACCCATG
Generation of 5’ arm for generation of S. aureus brnQ3::Tet allele

brnQ3 3’F- PstI
brnQ3 3’R- SmaI

TTCTGCAGCAACGATATTAGGCTATCTAGTCGGC
TTCCCGGGAGCTCGTTGAGCTGCTATTTTCC
Generation of 5’ arm for generation of S. aureus brnQ3::Tet allele

brnQ1SA5’F-KpnI
brnQ1SA3’R-SacI

GATCGGTACCGTTCTTAACTTACGCCC
GATCGAGCTCCAGTTGTTCAATATAAG
Cloning of S. aureus brnQ1

brnQ2SA5’F-KpnI
brnQ2SA3’F-SacI

GATCGGTACCTTTCCAACTTACTTTCA
GATCGAGCTCTCAATAGACAGACGGT
Cloning of S. aureus brnQ2

brnQ3SA5’F-KpnI
brnQ3SA3’F-SacI

GATCGGTACCCATGTGTTTTGTTTCTG
GATCGAGCTCTAATGGCGAGACTCCT
Cloning of S. aureus brnQ3

rpoB-76-F
rpoB-232-R

AGAGAAAGACGGCACTGAAAACAC
ATAACGACCCACGCTTGCTAAG
RT-PCR for rpoB expression in S. aureus
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brnQ1-416-Fw
brnQ1-602-Rv

TGCGAGAAAGCCATCAAG
GTATTGTATCCATCTAAAAAGCCG
RT-PCR for brnQ1 expression in S. aureus

brnQ3-qPCR-F
brnQ3-qPCR-R

TTGGGTTTACGCTCTTCG
CACCTACAATCACACCTAATAATG
RT-PCR for brnQ3 expression in S. aureus
a
Restriction sites are underlined.

2.2.3

Radioactive transport assays

The protocol for transport was adapted from a previously-described protocol (40). Cultures
were grown overnight at 37°C in complete CDM and sub-cultured into complete CDM at a
starting OD600 of 0.1. Bacteria were grown to mid-exponential phase (OD600 of 1.0),
harvested by filtration on 0.45-μm pore-size membrane filters, and washed with PBS before
being resuspended in CDM lacking amino acids. Cells were heated at 37°C for 10 minutes
prior to the assay. The 14C-labeled amino acid of interest (Perkin Elmer, MA) was added to
cells at a final concentration of 1 μM. An aliquot of cells was removed at 20, 40, and 60 s and
rapidly filtered through 0.45-μm membrane filters. The filters were immediately washed with
10 mL of 0.1 M LiCl2 at room temperature. Filters were dried and placed in scintillation vials
containing 4 mL of Cytoscint™ scintillation cocktail (Fisher Scientific).

14

C radioactivity

was measured using the LS 6500 scintillation system (Beckman).
To determine the Michaelis-Menten constant, cells, prepared as described above, were
incubated with 500 nM, 1 μM, 2 μM, or 4 μM of a

14

C-labeled amino acid. An aliquot of

cells was filtered as described above after 20 s. The initial velocity of uptake for each
substrate concentration was plotted to determine transport kinetics, and the Km and Vmax
values were extrapolated.

2.2.4

qPCR

qPCR was performed as described previously (31). In brief, RNA was prepared from 5-mL
cultures of 3 biological replicates of S. aureus strains grown in TSB to an OD600 of 0.6, or in
CDM to an OD600 of 1.0. Cells were collected and RNA was extracted using an Aurum Total
RNA Mini Kit as described by the manufacturer (Bio-Rad; Hercules, CA). RNA (500 ng)
was reverse transcribed using SuperScript II (Invitrogen; Carlsbad, CA) and PCR-amplified
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using SensiFast SYBR (Bioline; Taunton, MA) and the primers described in Table 2.2. Data
were normalized relative to expression of the reference gene rpoB.

2.2.5

Murine model of systemic S. aureus infection

All protocols were reviewed and approved by the University of Western Ontario's Animal
Use Subcommittee, a subcommittee of the University Council on Animal Care. Seven-weekold BALB/c mice were purchased from Charles River Laboratories (Wilmington, MA) and
housed in microisolator cages. Bacteria were grown to exponential phase (OD600 of
approximately 3.0) in TSB, pelleted by centrifugation, washed twice in PBS, and
resuspended in PBS. Bacterial suspensions in 100-μL volumes were administered via tail
vein injection (6-7 × 106 CFU). Four days post-challenge kidneys and livers were aseptically
excised and placed in 4-mL volumes of PBS containing 0.1% (v/v) Triton X-100 in a sterile
15-mL conical tube. Organs were homogenized for 10 s, and bacterial loads were calculated
following serial dilution on TSB agar plates. Data are presented as Log10 CFU recovered per
organ, or organ pair in the case of kidneys. Data were analyzed using the Student’s unpaired
t-test and P values of <0.05 were considered to indicate statistical significance.
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2.3 Results
2.3.1

Identification of brnQ genes in USA300 and generation of
mutant strains

The brnQ genes identified in the Majerczyk et al. and Pohl et al. studies (17, 28) are allelic
with brnQ1 (SAUSA300_188) and brnQ2 (SAUSA300_306) in USA300 FPR375.
Bioinformatics

analyses

revealed

a

third

potential

brnQ

paralog

encoded

by

SAUSA300_1300 with 35% identity to BrnQ1 and 38% identity to BrnQ2; we designated
this gene brnQ3. BrnQ3 has 100% amino acid sequence identity to the encoded product of a
brnQ gene previously cloned from S. aureus RN450, however its function as a BCAA
transporter was never formally tested (41). The three paralogs share significant sequence
similarity with the BrnQ1 protein from Lactobacillus delbüeckii and one another (Figure
2.2A); BrnQ1 vs. BrnQ2 54%, BrnQ1 vs BrnQ3 54%, BrnQ2 vs BrnQ3 57%. The proteins
are similar in length; BrnQ1 (451 aa), BrnQ2 (435 aa), BrnQ3 (447 aa) and TMPred predicts
they all have 12 transmembrane domains. Searches of the databases using HHPred revealed
the top hits to be transmembrane transporters for a variety of substrates. The genes are
located at independent loci in the USA300 genome and a CodY box (i.e. CodY-binding
motif) is positioned 117 bp upstream of the brnQ1 start codon and 85 bp upstream of the
brnQ2 start codon (Figure 2.2B). To ascertain a function for each of the brnQ paralogs, inframe, markerless deletions of the brnQ1 and brnQ2 coding regions were constructed and a
tetracycline resistance cassette was used to replace the majority of the brnQ3 coding region.
A triple mutant, herein referred to as brnQ1-2-3, was also constructed.

2.3.2

BrnQ1 transports Ile, Leu, and Val

To assess the specific role of each of the BrnQ transporters, we performed uptake assays with
radiolabeled BCAAs. Cells were grown in a chemically defined media (CDM) to lateexponential phase (OD = 1), a growth phase that we ensured, using qPCR, did not
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Figure 2.2 Protein sequence alignment and genomic context for the three brnQ paralogs
in USA300.
A) Amino acid sequence comparison of the BrnQ proteins in USA300 FPR3757 to the BrnQ
protein in Lactobacillus delbrückii (Accession: P54104.1). Dark blue = 4/4 sequence
conservation; Medium blue = 3/4 sequence conservation; light blue = 2/4 sequence
conservation; no highlight = no sequence conservation. B) Genomic context of brnQ genes in
USA300 FPR3757. Abbreviations: HYP = Hypothetical protein. RocD = Ornithine-oxo-acid
aminotransferase. C) Expression of brnQ1 was measured in the WT strain and codY mutant
grown to mid-exponential phase in either TSB or Complete CDM and normalized to
expression of the reference gene rpoB. Data are the mean of 3 biological replicates +/- SD.
Statistical significant was determined by a Student’s t-test. * P < 0.05; ns = not significant.
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demonstrate CodY-dependent repression of the brnQ genes (Figure 2.2C). We measured
uptake of BCAAs in the single mutants and also the brnQ1-2-3 mutant complemented with
each gene provided in trans. We observed that, compared to WT, uptake of each of Leu, Ile
and Val was decreased in the brnQ1 mutant (Figure 2.3). While the brnQ1 mutant was
similar to the brnQ1-2-3 mutant in terms of Leu and Val transport, brnQ1-2-3 had decreased
Ile uptake compared to the brnQ1 mutant, suggesting the involvement of one of the other two
transporters in Ile uptake. Importantly, expression of brnQ1 in trans (on pSO1) in the brnQ12-3 mutant resulted in increased uptake of each of Ile, Leu and Val to levels at or above those
seen in WT Figure 2.3. Together, these data indicate that BrnQ1 is capable of transporting all
three BCAAs.

2.3.3

BrnQ2 is an Ile transporter

Using the approach described in the preceding section, we next determined the substrate
specificity of BrnQ2. Relative to WT, transport of Ile, Leu and Val was not decreased in the
brnQ2 mutant but was, in fact, increased (Figure 2.4). Given the just-described data detailing
the involvement of BrnQ1 in transport of the three BCAAs, we attribute the transport seen in
the brnQ2 mutant strain to increased expression of brnQ1 (see below). When we examined
uptake in the brnQ1-2-3 mutant overexpressing brnQ2 in trans (on pSO2), we found that Leu
and Val transport was not restored, while uptake of Ile was restored (Figure 2.4). These data
implicate BrnQ2 as a transporter selective for Ile, with little to no role in transport of Leu and
Val, at least under the conditions used in this study.

2.3.4

BrnQ3 is not a functional BCAA transporter

Similar to the assays described in the preceding sections, we assessed BCAA transport in the
brnQ3 mutant to validate its predicted function (41). Our results demonstrate that transport of
Ile, Leu and Val were not affected in this strain, relative to WT, and that expression of brnQ3
in trans (on pSO3) in the brnQ1-2-3 mutant background did not appreciably restore transport
of any of the three BCAAs (Figure 2.5). Since this was a negative result, we used qPCR to
confirm that brnQ3 was expressed from pSO3 in the
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Figure 2.3 BrnQ1 transports isoleucine, leucine and valine.
Cells were harvested from cultures grown to mid-late exponential phase in complete CDM.
Transport of 14C-labeled BCAAs, as indicated, was measured at 20, 40 and 60 seconds.
pRMC2 = empty vector; pSO1 = pRMC2::brnQ1. Data points shown are the mean of three
biological replicates +/- SD.
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Figure 2.4 BrnQ2 transports isoleucine.
Cells were harvested from cultures grown to mid-late exponential phase in complete CDM.
Transport of 14C-labeled BCAAs, as indicated, was measured at 20, 40 and 60 seconds.
pRMC2 = empty vector; pSO2 = pRMC2::brnQ2. Data points shown are the mean of three
biological replicates +/- SD.
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Figure 2.5 BrnQ3 in not a BCAA transporter.
Cells were harvested from cultures grown to mid-late exponential phase in complete CDM.
Transport of 14C-labeled BCAAs, as indicated, was measured at 20, 40 and 60 seconds.
pRMC2 = empty vector; pSO3 = pRMC2::brnQ3. Data points shown are the mean of three
biological replicates +/- SD.
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Figure 2.6 Expression of brnQ1 and brnQ3 in strains bearing complementation vectors.
Cells were grown to mid-exponential phase in complete CDM and RNA was isolated.
Expression of brnQ1 and brnQ3 was measured and normalized to expression of the reference
gene rpoB. Data are the mean of 3 biological replicates +/- SD.

66

brnQ1-2-3 mutant to levels comparable to those of brnQ1 expressed from pSO1 (Figure 2.6).
Combined, these data led us to conclude that BrnQ3 does not function as a transporter of
BCAAs, at least under the conditions used in this study. Mutation of the brnQ3 gene was
previously identified as causing salt-sensitivity in S. aureus strain RN450 (42). To examine
this phenomenon further, we streaked USA300, along with its isogenic brnQ1, brnQ2 and
brnQ3 mutants on TSB agar and TSB agar containing 2M NaCl. Although all strains grew
relatively slower on 2M salt-containing agar plates, mutation of the brnQ genes had no effect
on the ability of strain USA300 to grow in the presence of high concentrations of NaCl,
including the brnQ1-2-3 mutant (Figure 2.7). It is likely that the absence of the salt-sensitive
phenotype in our study is due to strain differences between RN450 and USA300, since the
assay was performed using identical media to that previously described (42).

2.3.5

Transporter kinetics

To gain further insight into the role of the three BrnQ paralogs in BCAA transport, we
determined the kinetic properties of BCAA transport in strains expressing each of BrnQ1,
BrnQ2 and BrnQ3 by measuring the initial velocity of uptake in response to varying substrate
concentration. The kinetic plots are shown in Figure 2.8, and apparent KM and Vmax data are
provided in Table 2.3. The data indicate that BrnQ1 is a major determinant of uptake of all
three BCAAs, while BrnQ2 appears specific to Ile, albeit with lower affinity for Ile than
BrnQ1.
Table 2.3 KM and Vmax values for the BrnQ transporters
Transporter
BrnQ1
BrnQ2

Leucine
KMa Vmaxa
1.62
6.85

Isoleucine
KM
Vmax
0.93 10.22
8.94 18.13

KM
1.79

Valine
Vmax
12.81

KM units μM, Vmax units pmol μg-1 min-1; units of activity are expressed relative to total
protein
Values are the average of three biological replicates ±SD.
a
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Figure 2.7 Mutation of brnQ genes does not render salt sensitivity on USA300.
Single colonies of WT USA300 and the brnQ single and triple mutants were streaked from
TSA onto either TSA or TSA containing 2 M NaCl. Plates were incubated at 37˚C for 24
hours, at which point growth was observed.
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Figure 2.8 Kinetics of BCAA transport in S. aureus
Cells were harvested from cultures grown to mid-late exponential phase in complete CDM
and incubated with 14C-labeled amino acid at concentrations of a 0.5 µM, 1 µM, 2 µM, or 4
µM for 20 s. Values are the mean of three independent cultures +/- SD.
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2.3.6

BrnQ1-mediated Leu and Val acquisition is required for optimal
growth of USA300 in CDM

We next sought to investigate the physiological role of the functional BCAA transporters in
meeting the nutritional requirements of S. aureus growth. To do so, we selected CDM,
described previously (31), enabling the limitation or omission of amino acids of interest. In
complete CDM, we consistently observed a slight growth delay for the brnQ1 mutant
compared to the WT strain (Figure 2.9A), indicating that BrnQ1 contributes to rapid growth
in this medium. In comparison, all strains grew equally well in TSB (Figure 2.10). We next
investigated the amino acid specificity of the growth phenotype in CDM. S. aureus has been
reported to be auxotrophic for Leu and Val despite the presence of BCAA biosynthetic genes
(15–17), indicating a critical role for BCAA uptake to support growth. First, to confirm the
auxotrophic phenotype of USA300, the WT strain was grown in complete CDM as well as
CDM with each BCAA omitted; CDM-Ile, CDM-Leu or CDM-Val. As expected, based on the
literature, a growth delay was not observed for WT USA300 grown in CDM-Ile compared to
complete CDM, indicating that USA300 is capable of de novo synthesis of Ile. In contrast,
we observed that growth of WT USA300 in CDM-Leu was significantly delayed for the first
12 hours of incubation, but by 24 hours the cells had attained an equivalent biomass to that
obtained in complete CDM (Figure 2.9B). For growth in CDM-Val, we observed an even
greater growth defect. A significant growth delay was seen through the initial 24 hours of
incubation, followed by growth that resulted in biomass equivalent to WT after 48 hours
(Figure 2.9B). This suggests that Leu and Val synthesis is delayed, possibly owing to the
repression of the biosynthetic genes by CodY, Gcp and/or unrecognized factors (17, 28, 43).
We observed that the growth delay in these media was consistent upon serial sub-culturing,
excluding the accumulation of suppressor mutations.
We next assessed the role of BrnQ1 in acquiring Leu and Val to promote early and rapid
growth, since the BCAA uptake data implicated BrnQ1 as the dominant Leu and Val
transporter. Growth of WT USA300 and brnQ1 was compared in complete CDM and CDM
with varying amounts of Leu and Val limitation. The brnQ1 mutant was impaired for growth
compared to WT USA300 upon limitation of Leu or Val to concentrations
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Figure 2.9 BrnQ1 is required for rapid growth in CDM limited for leucine or valine.
A) Strains were pre-grown in complete CDM and sub-cultured into complete CDM. Growth
was monitored until stationary phase was reached. B) WT USA300 was grown in complete
CDM and sub-cultured into complete CDM, or CDM lacking Ile, Leu, or Val. Growth yield
was monitored at 12, 24, and 48 hrs. C-D) Strains were pre-grown in complete CDM and
sub-cultured into CDM where all amino acids were present at the same concentration as in
CDM, except for alterations to the concentration of Leu (panel C) or Val (panel D). Growth
yield was measured at 12 hrs. In panels E and F, growth curves were performed on the strains
as indicated. Cultures were pregrown in complete CDM and sub-cultured into CDM where
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all amino acids were present at the same concentrations as in CDM, except that Leu was 1%
the concentration of that in complete CDM (panel E) and Val was 1% the concentration of
that in complete CDM (panel F). pRMC2 = empty vector; pSO1 = pbrnQ1; pSO2 = pbrnQ2,
pSO3 = pbrnQ3. Data shown are the mean of three biological replicates +/- SD and were
analyzed using the Student’s t-tests (compared to WT). ** P<0.01, *** P<0.001.

Figure 2.10 The brnQ genes are not required for growth of USA300 in TSB.
WT USA300, the isogenic mutants, and the triple mutant were pre-grown in TSB to midexponential phase, and then sub-cultured to a starting OD600 of 0.0025 nm in TSB. Growth
was monitored at the indicated time points until stationary phase was reached. Data are mean
+/- SD.
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≤5% of that in complete CDM (complete CDM contained 684 μM Leu and 684 μM Val)
(Figure 2.9C,D). Growth of the brnQ1 mutant was fully restored to WT levels upon
complementation with brnQ1 in trans (Figure 2.9C,D).
To investigate the possible involvement of BrnQ2 and BrnQ3 in the acquisition of Leu or Val
for growth, we limited these two amino acids individually to 1% of the concentration in
complete CDM, and compared the growth, over 24 hours, of WT to that of the brnQ1-2-3
mutant carrying empty vector or the brnQ genes. We observed that the brnQ1-2-3 mutant, as
expected based on the above-described data, was impaired for growth (Figure 2.9E,F), and
neither vector expressing brnQ2 or brnQ3 restored this defect. In contrast, expression of
brnQ1 allowed rapid growth such that the strain grew quicker than WT in media limited for
Leu (Figure 2.9E). Overexpression of brnQ1 had an even more pronounced effect on the
growth enhancement of S. aureus in media limited for Val (Figure 2.9F). Combined, our data
indicate that BrnQ1-mediated Leu and Val acquisition is required for rapid growth of S.
aureus when these amino acids are limited.

2.3.7

Mutation of brnQ2 results in over-expression of brnQ1

The data illustrated in Figure 2.4 demonstrated that a brnQ2 mutant transported Ile, Leu and
Val to levels higher than WT. This was an interesting observation that led us to investigate
the possible regulatory effect of a brnQ2 mutation on brnQ1 expression, given that our data
have shown that BrnQ1 is a major Ile, Leu and Val transporter. As shown in Figure 2.11A,
qPCR demonstrated that brnQ1 expression was over 40-fold higher in the brnQ2 mutant than
in WT. We confirmed that this phenomenon was specifically due to mutation of brnQ2 and
not some secondary mutation in the brnQ2 mutant since complementation of the brnQ2
mutant with brnQ2 in trans reversed expression of brnQ1 to levels that were even lower than
in WT.
Given that a mutation of brnQ2 enhances expression of brnQ1, we hypothesized that a
brnQ2 mutant would grow quicker than WT in media limited for either Leu or Val. We
compared the growth of selected strains in media that contained 1% of the concentration of
either Leu or Val found in complete CDM. In support of our hypothesis, we observed that a
brnQ2 mutant demonstrated early and rapid growth, compared to WT, in media limited for
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Leu, and more so in media limited for Val. The growth kinetics of this mutant were virtually
identical to a brnQ1 mutant overexpressing brnQ1 from a plasmid (Figure 2.11B,C).

2.3.8

BrnQ1 is required for USA300 fitness in vivo

We next investigated the contribution of BCAA acquisition to the fitness of USA300 in vivo
using an established bacteremia murine model of infection. Groups of ten female Balb/c mice
were infected via tail vein injection with 5-7 x 106 CFU of WT USA300 or the isogenic
mutant. Mice infected with either WT or the brnQ1 mutant were sacrificed on day four postinfection and the bacterial burden in livers and kidneys was assessed. Mice infected with the
brnQ1 mutant had significantly lower CFUs in the kidneys and livers compared to WT
USA300 (Figure 2.12A,B), suggesting that USA300 encounters BCAA limitation in vivo and
that BrnQ1 is necessary for their acquisition in order to meet growth requirements.
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Figure 2.11 Mutation of brnQ2 results in overexpression of brnQ1.
A. The expression level of brnQ1 was evaluated in S. aureus strains, as indicated. Data was
normalized relative to the expression of rpoB, and expression of brnQ1 in WT cells was set
to 1 as the comparator. B-C. Cultures were pregrown in complete CDM and sub-cultured into
CDM where all amino acids were present at the same concentrations as in CDM, except that
Leu was 1% the concentration of that in complete CDM (panel B) and Val was 1% the
concentration of that in complete CDM (panel C). pRMC2 = empty vector; pSO1 = pbrnQ1.
Data shown are the mean of three biological replicates +/- SD.
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Figure 2.12 BrnQ1 is required for full S. aureus virulence in a mouse model of systemic
infection.
Balb/c mice were infected with 5-7 x 106 CFU of USA300 (n=9) or ΔbrnQ1 (n = 10) via tail
vein injection. Mice were sacrificed on day four of infection and A) kidneys and B) livers
were harvested, homogenized and dilutions plated for CFU determination. Data were
analyzed using the Student's unpaired t-test. * P< 0.05, *** P< 0.001.
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2.4 Discussion
S. aureus necessitates expression of transporters for Leu and Val acquisition that would allow
for growth, since it has been reported to be auxotrophic for Leu and Val, despite encoding the
genes for biosynthesis (15, 16). Here, we demonstrate that BrnQ1 plays a dominant role in
meeting Leu and Val nutritional requirements in vitro, especially in a medium containing
either of these amino acids in the low micromolar range, and postulate also in vivo since a
brnQ1 mutant is attenuated in vivo. In contrast, BrnQ2 is selective for Ile and BrnQ3 does not
function as a BCAA transporter. Although BrnQ3 was previously identified to contribute to
the osmotolerance of S. aureus, we were unable to replicate this finding. Our ongoing studies
will investigate the ligand specificity of BrnQ3, and the importance of this is demonstrated
by the finding by Benton et al., that a brnQ3 mutant is attenuated in vivo (44).
Our observation that USA300 is able to grow in the absence of exogenous Leu or Val
contrasts previous reports that S. aureus is auxotrophic for these amino acids. This is likely
explained by the extension of the growth period monitored here, since appreciable growth of
USA300 in media lacking Leu or Val is not observed until 24 and 48 hours, respectively
(Figure 2.9). We presume the biosynthesis of Leu and Val is de-repressed at the later stages
of growth, as we excluded the possibility of development of suppressor mutations. At
present, the regulatory mechanisms that govern the regulation of ILV synthesis in these
conditions is not known, but plausible mediators of repression include CodY and Gcp, both
known repressors of the ilv-leu biosynthetic genes in S. aureus (17, 28, 43). Although we did
not investigate this in further detail, of note, we observed that growth in CDM-LEU and CDMVAL

(i.e. growth dependent on Leu and Val synthesis) is iron-dependent. Indeed, several

enzymes involved in BCAA biosynthesis contain Fe-S clusters, including IlvD, LeuC, and
LeuD. LeuCD are repressed in Bacillus subtilis upon iron starvation (45, 46) and a similar
link between iron availability and BCAA biosynthesis might exist in S. aureus. This
phenotype is relevant when considering the levels of BCAA biosynthesis in vivo, as iron is
limited during S. aureus infection (47) and consequently might impart a greater importance
on BCAA acquisition in vivo.
BrnQ1 plays a predominant role in BCAA transport, as demonstrated by both radioactive
transport assays and the growth assays where Leu and Val are present in low micromolar
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concentrations (Figure 2.3, Figure 2.9). However, two lines of evidence suggest the presence
of at least one additional BCAA transporter in S. aureus. First, a brnQ1 mutant and a brnQ12-3 mutant are not defective for growth, compared to WT, even at early timepoints, in CDM
media containing 100 µM or higher concentrations of Leu or Val, and our transport assays
indicate that the brnQ1-2-3 mutant still transports some Ile, Leu and Val (Figure 2.3, Figure
2.4, Figure 2.5). We are currently investigating additional genes that contribute to BCAA
transport, such as a gene homologous to the CodY-regulated transporter BcaP described in
Lactococcus lactis (9). BcaP functions as the high-affinity BCAA transporter in L. lactis,
whereas BrnQ is the low affinity transporter (9). Given that BrnQ1 in USA300 is necessary
for growth when Leu or Val are in low micromolar concentrations, and not when they are
present at higher concentrations in the growth medium, we predict that BrnQ1 is the highaffinity transporter in this species. In line with this, the brnQ1 mutant is attenuated in vivo,
suggesting that BrnQ1 functions as a primary means of BCAA transport during infection.
It will be interesting to consider in future studies the effects of mutating brnQ1 and brnQ2 on
CodY activity. The up-regulation of brnQ1 in the brnQ2 mutant, and the subsequent
increased ability of S. aureus to scavenge Leu and Val, might involve a decrease in CodY
activity upon Ile depletion. Ongoing studies in our lab are addressing the effects of
manipulating intracellular levels of CodY effector molecules, and their implications on the
expression of CodY-regulated genes.
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Chapter 3

3

The role of BcaP in BCAA transport

3.1 Introduction
Staphylococcus aureus, and its methicillin-resistant variant, is associated with significant
human infectious morbidity and mortality. It is capable of infecting nearly every body site to
cause infections that range from mild skin and soft tissue infections to life-threatening
pneumonia, necrotizing fasciitis, and sepsis (1–4). It is also an asymptomatic colonizer of the
nares in approximately one third of the population (5). The synthesis and acquisition of
nutrients are critical to support S. aureus metabolism and virulence factor production and are
prerequisites for infection and colonization (6–9). Such nutrients include amino acids, which
S. aureus is presumably starved for in the host given that genes for amino acid synthesis and
transport are up-regulated in vivo (6, 10). Yet the specific amino acid requirements of S.
aureus in diverse host niches and the mechanisms to maintain these nutrients are not fully
understood.
The branched-chain amino acids (BCAAs; Ile, Leu, Val) are vital nutrients for bacterial
physiology, as their importance extends beyond supporting high levels of protein synthesis.
In most Gram-positive bacteria, the BCAAs are precursors for the synthesis of branchedchain fatty acids (BCFAs), which are a major constituent of membrane fatty acids and
include Leu/Val-derived iso-fatty acids and Ile-derived anteiso-fatty acids. In S. aureus,
BCFAs comprise 65% of membrane fatty acids, and straight-chain fatty acids comprise 35%
(11). BCFA composition is adjusted to regulate membrane fluidity, an alternative strategy to
the incorporation of unsaturated fatty acids, which are toxic to S. aureus (12). Of the BCFAs,
anteiso-fatty acids are most important for promoting a more fluid membrane and as such,
their abundance in the membrane is increased at low temperatures to support growth (11, 13–
17). The iso:anteiso ratio is also important for pH stress tolerance, resistance to membrane
stressors including antimicrobial peptides, and virulence (11, 14, 18, 19), thus the BCFAs
serve an important role in adaptation to various environmental conditions.
Intracellular levels of BCAAs are monitored by the global regulatory protein CodY (20–22).
CodY is a highly conserved transcriptional repressor in low %mol G+C Gram-positive

83

bacteria that regulates >100 genes involved in amino acid and peptide metabolism and
transport in response to BCAAs and GTP (23–25). CodY also regulates virulence factors in
S. aureus (26–29), implicating CodY as an important link between the metabolic status of the
cell and virulence. Identifying the mechanisms that maintain intracellular levels of BCAAs is
therefore a key step towards understanding how CodY activity is regulated.
S. aureus was previously reported to be auxotrophic for Leu and Val, despite encoding the
ilv-leu operon required for BCAA synthesis (25, 30). In replicating this, we found that in
fact, S. aureus is capable of synthesizing Leu and Val, but it represses their synthesis during
early stage growth (Figure 2.9). This indicated that S. aureus prefers to acquire these
nutrients and must therefore be able to scavenge BCAAs from the host. Indeed, free BCAAs
are available to S. aureus at sites of infection or colonization in the micromolar range (50 –
300 μM except for Ile which is undetectable in nasal secretions) (6, 31). We have therefore
focused our studies on investigating mechanisms of BCAA transport. BCAA transporters in
other Gram-positive bacteria include the secondary transporters BrnQ, BraB and BcaP (32–
34). We previously characterized three BrnQ homologs (BrnQ1, BrnQ2, and BrnQ3) in the
community-associated methicillin-resistant S. aureus strain USA300. We determined that
BrnQ1 transports all three BCAAs, BrnQ2 is a dedicated Ile transporter, and BrnQ3 did not
appear to function as a BCAA transporter. Yet a strain lacking all three brnQ genes remained
capable of BCAA transport (Figure 2.3). BLAST searches revealed that USA300 also
possesses a BcaP homolog. In this study, we describe the role of BcaP in BCAA acquisition
and demonstrate the importance of BCAA transport to S. aureus growth, membrane BCFA
content, and fitness in vivo.

3.2 Materials and Methods
3.2.1

Strains and growth conditions

Bacterial strains and plasmids used in this study are described in Table 3.1. The wild type
(WT) strain in all experiments is the MRSA isolate pulsed-field gel electrophoresis type
USA300 LAC that has been cured of the erythromycin resistance plasmid. For experiments
involving S. aureus grown in tryptic soy broth (TSB) (EMD Millipore, Billerica, MA), two to
three colonies were inoculated from TSB agar into TSB and grown to mid-exponential phase
at 37˚C, then sub-cultured into fresh TSB to a starting OD600 equivalent of 0.0025. For
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growth curves performed in chemically defined medium (CDM), described previously (See
Section 2.2.1), two to three colonies were inoculated from TSB agar into CDM and were
grown to mid-late-exponential phase at 37˚C, then sub-cultured to a starting OD600 equivalent
of 0.0025 in either complete CDM or CDM with altered concentrations of amino acids. The
brnQ1,brnQ2,brnQ3,bcaP mutant was treated the same, however media was supplemented
with 10 mg mL-1 of Bacto™ tryptone (BD Biosciences; Sparks, MD) to support growth.
Strains were grown at 37˚C or 25˚C where indicated. Growth curves were performed either
in 100-well plates and read using the Bioscreen C visible spectrophotometer (Growth Curves
USA; Piscataway, NJ), or in flasks using a flask:volume ratio of at least 5:1. Where required,
ampicillin (100 μg mL-1), chloramphenicol (10 μg mL-1), erythromycin (3 μg mL-1),
streptomycin (500 μg mL-1) and tetracycline (4 μg mL-1) were added to the growth medium.

3.2.2

Mutagenesis and construction of plasmids

Strains containing a transposon insertion in either the bcaP gene (bcaP::N) or crtM
(crtM::N) gene were identified in the Nebraska Transposon Mutant Library (35). The
bcaP transposon was transduced into our laboratory strain of USA300 and into the brnQ1,
brnQ1-2-3, brnQ1-2 and brnQ1-3 backgrounds using phage 80α. The same method was used
to transduce the crtM transposon into WT USA300 and the brnQ1 mutant. Transposon
insertions were confirmed by PCR. All plasmids were first constructed as shuttle vectors in
Escherichia coli DH5α. Once confirmed, plasmids were subsequently electroporated into S.
aureus RN4220 as an intermediate host, and then into
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Table 3.1 Bacterial strains and plasmids used in this study
Strain/Plasmid
Description a

Source or
reference

S. aureus
USA300
RN4220
bcaP
brnQ1
brnQ1-bcaP
brnQ1-2-3
brnQ1-2-3-bcaP

brnQ1-2-bcaP
brnQ1-3-bcaP
codY
crtM
brnQ1-crtM

USA300 LAC cured of antibiotic resistance
plasmid
rK- mK+ ; capable of accepting foreign DNA
USA300 bcaP::ΦNΣ; EmR (SAUSA300_2538)
USA300 ΔbrnQ1
USA300 ΔbrnQ1 bcaP::ΦNΣ; EmR
USA300 ΔbrnQ1 ΔbrnQ2 brnQ3::Tc; TcR
USA300 ΔbrnQ1 ΔbrnQ2 brnQ3::Tc bcaP::ΦNΣ;
EmR, TcR

(36)
(37)
(35)
Chapter 2
This study
Chapter 2
This study
This study
This study

USA300 ΔbrnQ1 ΔbrnQ2 bcaP::ΦNΣ; Em
USA300 ΔbrnQ1 brnQ3::Tc bcaP::ΦNΣ; EmR,
TcR
USA300 codY:: ΦNΣ; EmR
(35)
R
USA300 crtM:: ΦNΣ; Em
(35)
USA300 ΔbrnQ1 crtM:: ΦNΣ; EmR
This study
R

E.coli
DH5α

Plasmids
pRMC2

F- ϕ80dlacZΔM15 recA1 endA1 gyrA96 thi-1
hsdR17 (rK− mK-) supE44 relA1 deoR Δ(lacZYAargF)U169phoA

Promega

Anhydrotetracycline-inducible expression vector; (38)
ApR in E. coli; CmR in S. aureus
pBrnQ1
pRMC2 containing brnQ1; CmR
(pSO1 from
Chapter 2)
R
pBcaP
pRMC2 containing bcaP; Cm
This study
pGYlux
Vector harboring promoterless luxABCDE
(39)
R
operon; Cm
pGYbrnQ1::lux
lux reporter vector with brnQ1 promoter
This study
pGYbcaP::lux
lux reporter vector with bcaP promoter
This study
a
Abbreviations: TcR, CmR, EmR and ApR designate resistance to tetracycline,
chloramphenicol, erythromycin and ampicillin, respectively.
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the desired S. aureus USA300 strains. Primers used for plasmid construction are listed in
Table 3.2.

3.2.3

RT-qPCR

Cultures were grown to mid-exponential phase (OD600 of 0.6 in TSB) and RNA was
extracted using an Aurum Total RNA Mini Kit as described by the manufacturer (Bio-Rad;
Hercules, CA). RNA (500 ng) was reverse transcribed using SuperScript II (Invitrogen;
Carlsbad, CA) according to manufacturers instructions and using 500 μg mL-1 of random
hexamers. cDNA was PCR-amplified using SensiFast SYBR ® (Bioline; Taunton, MA). The
primers used and their reaction efficiencies are listed in Table 3.2. Data were normalized
relative to expression of the reference gene rpoB.
Table 3.2 Oligonucleotide primers used for cloning and qPCR
Oligonucleotides
bcaP-KpnI-For
bcaP-EcoRI-For

Sequencea
TTTGGTACCGCGTAACGACGCTATTTAAA
TTTGAATTCTGGATGTTAATCAGATGGGA
For cloning bcaP into pRMC2

rpoB-For
rpoB-Rev

AGAGAAAGACGGCACTGAAAACAC
ATAACGACCCACGCTTGCTAAG
qPCR for rpoB expression in S. aureus

brnQ1-For
brnQ1-Rev

TGCGAGAAAGCCATCAAG
GTATTGTATCCATCTAAAAAGCCG
qPCR for brnQ1 expression in S. aureus

bcaP-For
bcaP-Rev

TTTACGCTACCTGGCATTG
CCCAAGAATAGGCTGAACC
qPCR for bcaP expression in S. aureus

brnQ1-lux-For
brnQ1-lux-Rev

GATCCCCGGGACATATACTTCCCCCCTTCG
GATCGTCGACCCGGCACCAAAGAATAAACC
For cloning brnQ1 promoter into pGYlux

bcaP-lux-For
bcaP-lux-Rev

GATCCCCGGGGCGTAACGACGCTATTTAAAGGC
GATCGTCGACGCCGGATCCTCTTTTCGTGCTA
For cloning bcaP promoter into pGYlux
a
Restriction sites are underlined.
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3.2.4

Radioactive transport assays

Cultures were grown overnight at 37°C in complete CDM and sub-cultured into complete
CDM at a starting OD600 of 0.1. Bacteria were grown to mid/late-exponential phase (OD600 of
1.0), harvested by filtration on 0.45-μm pore-size membrane filters, and washed with PBS
before being re-suspended in CDM lacking amino acids. Cells were warmed to 37°C for 10
minutes prior to the assay. The

14

C-labeled amino acid of interest (Perkin Elmer, MA) was

added to cells at a final concentration of 1 μM. An aliquot of cells was removed at 20, 40,
and 60 s and rapidly filtered through 0.45-μm membrane filters. The filters were immediately
washed with 10 mL of 0.1 M LiCl2 at room temperature. Filters were dried and placed in
scintillation vials containing 4 mL of Cytoscint™ scintillation cocktail (Fisher Scientific).
14

C radioactivity was measured using the LS 6500 scintillation system (Beckman).

Radioactivity was normalized to total protein; 1 mL of culture with an OD of 1.0
corresponded to approximately 115 μg of protein. For competition assays, 1 mM of nonlabeled amino acid was added in the presence of 1 μM of either 14C-Leu or 14C-Ile and cells
were filtered at 60 s and processed as above.
To determine transport kinetics, cells, prepared as above, were incubated with 500 nM, 1 μM,
2 μM, or 4 μM of a

14

C-labeled amino acid. An aliquot of cells was filtered as described

above after 20 s. The velocity of uptake for each concentration was normalized to total
protein and plotted to determine the Michaelis-Menten equation and the apparent KM and
Vmax.

3.2.5

Lux reporter gene assays

The WT USA300 strain and codY mutant containing either pGYbrnQ1::lux or pGYbcaP::lux
were grown to mid-late exponential phase in complete CDM and sub-cultured to a starting
OD600 of 0.01 (200 µL/well) of complete CDM in a clear bottom 96-well Microfluor 2 White
Plate (Thermo). Plates were incubated at 37˚C with constant shaking. Luminescence and
OD600 were ready at hourly intervals on the BioTek Synergy H4 Hybrid Reader (BioTek,
Winooski, VT) with 1 s of integration and a gain of 200.
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3.2.6

Membrane fatty acid analysis and staphyloxanthin quantification

Strains were grown overnight in either TSB or CDM and sub-cultured to an OD600 of 0.05 in
the same media. Cells were harvested at mid-exponential phase (OD600 0.4-0.6) by
centrifugation at 3000 x g at 4°C for 15 minutes, and the pellet was washed 3 times with cold
sterile distilled water. The fatty acids in the bacterial cells (30 to 40 mg [wet weight]) were
saponified, methylated, and extracted for fatty acid methyl ester (FAME) analysis. The
resulting methyl ester mixtures were separated using an Agilent 5890 dual-tower gas
chromatograph and the fatty acyl groups were identified using the MIDI microbial
identification system (Sherlock 4.5 microbial identification system) at Microbial ID, Inc.
(Newark, DE) (40, 41). Minor fatty acids (<1% of the total) are not reported in the tables.
Quantification of the carotenoid pigment was performed as per the warm methanol extraction
protocol described previously (42, 43). Cells were harvested from strains grown overnight in
CDM, and carotenoid was extracted with warm (55˚C) methanol for 5 min. The absorbance
at 465 nm of the supernatant after centrifugation was measured and expressed relative to the
OD600 of overnight cultures.

3.2.7

Antibiotic susceptibility assays

The minimum inhibitory concentrations (MIC) for Daptomycin (DAP) and Polymyxin B
(PMB) were determined based on growth of S. aureus strains in tubes containing 2 mL of
complete CDM with a range of 2-fold dilutions of each antibiotic. PMB (Sigma-Aldrich) was
resuspended in H2O to a stock concentration of 50 mg mL-1 and DAP (Cayman Chemicals)
was resuspended in 100% DMSO to a stock concentration of 5 mg mL-1. The concentration
of DMSO did not exceed 5% of the culture volume in any experiment. Cells were grown to
mid-late-exponential phase in complete CDM and sub-cultured into CDM containing
antibiotics at a starting CFU of approximately 1 x 105. Cultures were incubated at 37˚C and
were monitored for visible growth after 24 h.

3.2.8

Murine model of systemic infection

All protocols were reviewed and approved by the University of Western’s Ontario Animal
Use Subcommittee, a subcommittee of the University Council on Animal Care. The systemic
infection was performed as previously described (See Section 2.2.5). Briefly, seven-week old
BALB/c mice purchased from Charles River Laboratories Canada Inc. were housed in
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microisolator cages. Strains were grown in TSB to mid-exponential phase, washed twice in
PBS, and resuspended in PBS. Mice were infected with approximately 6 x 10 6 – 7 x 106 CFU
of S. aureus via tail-vein injection. Mice were monitored for activity and weight changes
every 24 hr for the duration of the experiment. Mice were sacrificed 96-hours post challenge
and kidneys, livers and hearts were removed, homogenized in 0.01% Triton X-100, and
plated on TSB agar to determine CFUs.

3.2.9

Murine nasal colonization model

All protocols were reviewed and approved by the University of Western’s Ontario Animal
Use Subcommittee, a subcommittee of the University Council on Animal Care. To evaluate
S. aureus nasal colonization, the endogenous murine microbiota, which are non-permissive to
S. aureus colonization, were depleted with use of streptomycin sulfate, as previously
described (44). Since S. aureus is not naturally resistant to Sm, Sm resistant colonies were
selected for independently in the WT and mutant backgrounds by plating overnight cultures
on TSB agar containing 500 μg ml-1 of streptomycin sulfate. Sm-resistant clones were
confirmed to be free of any obvious growth defects, compared to the Sm-sensitive colonies,
during growth in TSB or CDM. Seven-week old C57BL/6 mice purchased from Charles
River Laboratories Canada, Inc. were housed in microisolator cages. Mice received 2 mg mL1

streptomycin sulfate in the drinking water 24 hr prior to inoculation with S. aureus, which

was changed every 3-4 days for the duration of the experiment. Strains were grown in TSB to
mid-exponential phase, washed twice in PBS, and resuspended in PBS. Isofluraneanesthetized mice were inoculated with 5 µL bacterial suspensions into each naris for a total
of 108 CFU of S. aureus and monitored over seven days. On day seven, mice were sacrificed
and the snout was excised, homogenized in PBS with 0.01% Triton X-100, and plated on
TSB agar for CFUs.

3.2.10

Statistics

All data were analyzed using the statistical tests indicated in figure legends using GraphPad
Prism version 6.0.
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3.3 Results
3.3.1

Identification of CodY-regulated bcaP as a BCAA transporter in
S. aureus

We hypothesized that one or more BCAA transporter(s) exist in S. aureus, in addition to the
three brnQ genes, since we previously demonstrated that uptake of Ile, Leu and Val is not
completely abolished in a brnQ1-2-3 mutant (Figure 2.3). We prioritized the gene
SAUSA300_2538 to investigate since it exhibited 34% and 63% total similarity to BcaP, a
BCAA transporter in Bacillus subtilis and Lactococcus lactis, respectively (32, 34). The
SAUSA300_2538 gene, hereafter referred to as bcaP, possesses a CodY-binding site (CodY
box) 102 base pairs upstream of the start codon (Figure 3.1A). Consistent with this, we
observed that expression of bcaP in S. aureus strain USA300 increased in the absence of
CodY activity (Figure 3.1B). This is in agreement with previous findings in S. aureus strains
Newman and UAMS-1, although the magnitude of bcaP up-regulation observed in USA300
is lower than what was previously reported, possibly a consequence of strain variation (25,
45).
To determine whether BcaP functions as a BCAA transporter, we mutated bcaP alone and in
combination with the brnQ genes and measured uptake of 14C-labeled Ile, Leu, or Val in the
various mutant strains. The bcaP mutation alone had a minor effect on transport of all three
BCAAs compared to the WT strain (Figure 3.2). However, when bcaP was mutated in the
brnQ1-2-3 mutant background, uptake of all three BCAAs was completely abolished (Figure
3.2A), indicating a clear role for BcaP in BCAA transport. Leu transport was completely
abolished in the brnQ1-bcaP mutant, suggesting that these are the only genes responsible for
Leu transport. Ile transport was reduced in the brnQ1- bcaP mutant compared to the bcaP
mutant alone, and introduction of the brnQ2 mutation into the brnQ1-bcaP mutant resulted
no Ile transport, indicating that the brnQ1, brnQ2 and bcaP genes all participate in Ile
transport.
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Figure 3.1 BcaP is a CodY-regulated gene in USA300.
A) Genomic context of bcaP in the USA300 FPR3757 genome. B) Expression of bcaP was
evaluated by RT-qPCR in WT USA300 and a codY mutant grown to an OD600 of 0.6 in TSB.
Data were normalized relative to the expression of rpoB, and expression of bcaP in WT cells
was set to 1 as the comparator. Data are the mean of three biological replicates +/- SD. Data
were analyzed using a Student’s unpaired t test. *** P ≤ 0.001.
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Unexpectedly, the brnQ1-bcaP mutant retained some Val transport (Figure 3.2A). The
addition of the brnQ3 mutation in the brnQ1-bcaP mutant background resulted in no Val
transport (Figure 3.2A), uncovering an involvement of BrnQ3 in Val transport that we
previously had overlooked, likely due to the transport activity of BcaP.
To confirm a direct role for BcaP in BCAA transport, we tested whether expression of bcaP
in trans could restore transport in the brnQ1-2-3-bcaP mutant. BcaP restored transport of all
three BCAAs in the quadruple mutant to levels comparable to WT or the quadruple mutant
complemented with BrnQ1 (Figure 3.2B), thus confirming the role of BcaP as a BCAA
transporter. Despite our observation that BrnQ3 contributes to Val transport (Figure 3.2B),
expression of brnQ3 from a complementation vector (confirmed using RT-qPCR; see Figure
2.6) was unable to restore Val transport in the quadruple mutant (data not shown). At this
point, we have no conclusive evidence that implicates BrnQ3 as a bona fide BCAA
transporter.
BCAA transporters in L. lactis and B. subtilis are capable of transporting amino acids
structurally similar to BCAAs (32, 34). To test the transport specificity of the BrnQ and BcaP
transporters in S. aureus, we investigated

14

C-Leu uptake with 10-fold, 100-fold, and 1000-

fold excess of each unlabeled amino acid. We first determined that 1000-fold excess was
required to reduce transport to less than 50%, and selected this as the condition for
subsequent experiments. Alanine, cysteine, methionine, and threonine were able to reduce
BrnQ1- or BcaP-mediated Leu transport whereas only aspartic acid was able to compete for
Ile transport mediated by BrnQ2 (Figure 3.3). The transport kinetics for these amino acids is
beyond the scope of this study, however we investigated whether BrnQ1 and BcaP are
required for growth in chemically defined media (CDM) with limiting concentrations of Ala,
Cys, Thr, or Met. The double mutant did not exhibit a growth delay in these media any more
so than in complete CDM (Figure 3.4), suggesting that either i) they bind to, but do not
transport these amino acids, ii) there are other transporters for these amino acids, or iii) at
least in the case of Ala, Thr, and Met (for which S. aureus is not auxotrophic) they are
synthesized inside the cell, masking a transport-dependent growth defect.
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Figure 3.2 BcaP is a BCAA transporter
A,B) Cells were harvested from cultures grown to mid-late exponential phase in complete
CDM, or CDM supplemented with 10 mg mL-1 tryptone in the case of the
brnQ1,brnQ2,brnQ3,bcaP mutant. Transport of 14C-labeled BCAA, as indicated, was
measured at 20, 40 and 60 seconds and expressed relative to total protein. Data points shown
are the mean of three biological replicates +/- SD.
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Figure 3.3 Non-BCAAs compete for BCAA transport.
The brnQ1brnQ2brnQ3bcaP mutant complemented with a vector expressing either A)
brnQ1 B) bcaP or C) brnQ2 was grown to mid-late exponential phase in complete CDM.
Cells were harvested and 1 μM of 14C-labeled A,B) Leu or C) Ile was added in the presence
of 1 mM of a non-labeled competing amino acid and uptake was measured at 60 seconds.
Data are the percentage of Leu/Ile uptake in the absence of a competitor. Data are the mean
of three biological replicates +/- SD.
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Figure 3.4 BrnQ1 and BcaP do not contribute to growth in media limited for nonBCAAs.
Strains were grown to mid-late exponential phase in complete CDM and sub-cultured to a
starting OD600 of 0.0025 in either A) complete CDM (670 μM Ala; 170 μM Cys; 20 μM
Met; 260 μM Threo) or B-E) CDM with a single amino acid reduced by 10-fold from its
concentration in complete CDM, as indicated. Data are the mean of three biological
replicates +/- SD.
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3.3.2

BrnQ1 is the predominant BCAA transporter required for growth
in media containing free amino acids

We previously demonstrated that despite encoding the BCAA biosynthetic operon, USA300
prefers Leu and Val acquisition over their biosynthesis during growth in CDM (Figure 2.9).
We therefore determined the biological relevance of each of BcaP and BrnQ1 in S. aureus for
growth in complete CDM, which contains excess concentrations of Leu and Val (684 μM). A
mutation in bcaP did not impede growth of USA300 in complete CDM, whereas a brnQ1
mutation resulted in a reduced growth rate (Figure 3.5A). Combining both mutations further
reduced the growth rate (Figure 3.5A). The growth of the brnQ1-bcaP mutant did not require
a compensatory mutation, as when these cells were plated for isolated colonies, picked and
re-inoculated into the same medium, an identical growth phenotype was observed. Thus,
either another transporter(s) or induction of BCAA synthesis is able to supply Leu and Val
for growth. To minimize the effects of the existence of a potentially low-affinity transporter,
we reduced the concentration of Leu or Val in the media by 10-fold. In Leu-limited CDM,
the bcaP mutant exhibited a growth rate comparable to the WT strain, whereas the brnQ1
mutant exhibited a growth lag of approximately 12 hr (Figure 3.5B). Addition of the bcaP
mutation into the brnQ1 mutant background extended the growth lag to ~14 hr (Figure 3.5B).
The bcaP mutant also grew comparably to the WT strain in Val-limited CDM, whereas the
brnQ1 and brnQ1-bcaP mutants both exhibited a growth lag of ~ 18 hr. Growth of the
brnQ1-bcaP mutant in all media could be restored to WT levels with the addition of multicopy complementation vectors expressing either brnQ1 or bcaP (Figure 3.5A-C). Together
these data indicate that BrnQ1 is the predominant transporter required for Leu and Val
acquisition during growth in media containing free amino acids, and BcaP contributes to Leu
acquisition, but only noticeably in the absence of BrnQ1.
To test whether the growth of the mutants in Leu- and Val-limited conditions following an
extended growth lag was the result of compensatory mutations, we plated the cultures that
eventually grew in these conditions and, using these cells, repeated the growth experiment in
the Leu- and Val-limited conditions. The brnQ1 and brnQ1-bcaP mutants
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Figure 3.5 BrnQ1 is the predominant transporter required for growth in free amino
acid containing medium.
Strains were grown in complete CDM to mid-late exponential phase and sub-cultured to a
starting OD600 of 0.0025 in either A) complete CDM (684 μM each Leu and Val) or CDM
where all amino acids were present at the same concentration as in complete CDM, except
for alterations to the concentration of Leu (panel B) or Val (panel C). Data are the mean
readable ODs of three biological replicates +/- SD. pRMC2 is the empty vector.
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from the Leu-limited CDM exhibited the same growth lag upon sub-culture into Leu-limited
CDM indicating that the eventual growth in this condition does not result in a geneticallyheritable compensatory mutation. Interestingly, the brnQ1 and brnQ1-bcaP mutant cultures
from Val-limited CDM were able to grow without a growth lag upon sub-culture into the
same condition and, in fact, both strains exhibited unimpeded growth in CDM with Val
omitted (data not shown). These data suggest that the growth of the brnQ1 and brnQ1-bcaP
mutants in the Val-limited media resulted in a genetically-heritable compensatory mutation
that likely results in Val biosynthesis. The identity of the mutation, or mutations, is currently
under investigation.

3.3.3

Predominance of BrnQ1 is dictated by promoter strength

We next investigated the underlying basis for the predominant role of BrnQ1 over BcaP for
growth in CDM. We determined the apparent KM and Vmax of each transporter using the
quadruple mutant complemented with either brnQ1 or bcaP. Both transporters had an
apparent KM for each BCAA in the low micromolar range (1-4 μM) (Table 3.3). Vmax values
further revealed that under the conditions where growth is assessed, both transporters are
functioning at maximum velocity, and in fact, the Vmax of BrnQ1 is lower than the Vmax of
BcaP (Table 3.3). These data indicate that, when over-expressed, both transporters function
comparably, and therefore transporter kinetics are not likely sufficient to explain their
different roles in growth.
We next turned to a lux promoter-reporter assay to determine the promoter activity of each of
brnQ1 and bcaP during growth, as we were not able to directly determine protein abundance
of each transporter due to lack of antibodies. Promoter activities of both brnQ1 and bcaP
were higher in a codY mutant compared to the WT strain (Figure 3.6A,B), confirming they
are both repressed by CodY. Notably, the promoter of brnQ1 drove higher expression of the
lux genes from the reporter plasmid than the bcaP promoter, which exhibited little/no lux
expression (Figure 3.6A,B), suggesting that brnQ1 expression is higher than bcaP. Since
CodY promoters do not necessarily respond equally to changes in the level of CodY activity
(29, 46), we also assessed promoter activity in the low Leu condition, and observed the same
trends in promoter activity as in complete CDM (data not shown). Together, with the
observation that over-expression of bcaP from a multi-copy plasmid restores growth of the
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brnQ1-bcaP mutant, these data suggest that the predominant role of BrnQ1 is due to protein
abundance and not differences in transport kinetics between the two transporters.

Table 3.3. Transporter kinetics
Transporter

Isoleucine
Leucine
Valine
a
KM
Vmax
KM
Vmax
KM
Vmax
BcaP
3.4 ±0.8
110 ±12
2.9 ±0.8
28 ±3
3.7 ±0.6
155 ± 12
BrnQ1
1.4 ±0.4
55 ±7
1.1 ±0.7
10 ±2
2.5 ±1.7
92 ± 39
a
-1
-1
KM units μM, Vmax units pmol μg min ; units of activity are expressed relative to total
protein
Values are the average of three biological replicates ±SD.
a

3.3.4

BCFA content in S. aureus membranes is dependent on BrnQ1

Branched-chain fatty acids (BCFAs) are synthesized from the BCAAs and comprise 50-65%
of total membrane fatty acids of S. aureus grown in rich media (11). Ile, Leu, and Val are
used for the synthesis of anteiso-fatty acids, odd-chained iso-fatty acids, and even-chained
iso-fatty acids respectively, with anteiso-fatty acids being the most abundant (11). Since S.
aureus relies on transporters to acquire the BCAAs, we hypothesized that transporter mutants
would lack the corresponding BCFAs in their membranes. When grown in complex media
(TSB), BCFAs made up 43% of total fatty acids in the WT strain and 48% of total fatty acids
in a brnQ1-bcaP mutant, with no difference in the proportion of anteiso- and iso-fatty acids
between strains (Table 3.4). These data suggest that, independent of the free amino acid
transporters BrnQ1 and BcaP, S. aureus is able to acquire BCAAs from peptide sources
present in a rich medium. In contrast, when grown in CDM, the proportion of BCFAs
increased to 76% of total fatty acids in the WT strain and 88% in the brnQ1-bcaP mutant,
with drastic differences in the proportions of anteiso- and iso-fatty acids between the WT and
mutant. Whereas BCFAs in the WT strain membrane included both anteiso- and iso-fatty
acids, BCFAs in the brnQ1-bcaP mutant membrane were derived solely from anteiso-fatty
acids, with no detection of Leu-derived odd-chain iso-fatty acids or Val-derived even-chain
iso-fatty acids. The absence of Leu- and Val-derived BCFAs in this strain was the
consequence of the brnQ1 mutation since the brnQ1 mutant alone lacked Leu- and Valderived BCFAs, whereas the whereas the fatty acid profile of the bcaP mutant resembled that
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Figure 3.6 Promoter activity of brnQ1::lux is higher than bcaP::lux
Growth (OD600; closed symbols) and relative luminescence units (RLU; open symbols) of
WT USA300 and the codY mutant harboring either A) the pGYbrnQ1::lux reporter vector or
B) the pGYbcaP::lux reporter vector. Strains were grown to mid-late exponential phase in
complete CDM and sub-cultured to an OD600 of 0.01 in complete CDM. Data are the mean
+/- SD of three biological replicates.
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of the WT strain (Table 3.4). Notably, the anteiso-fatty acid content was not affected in a
strain lacking all Ile transporters (e.g. brnQ1-brnQ2-bcaP) in comparison to the WT strain
(Table 3.4). Altogether, these data indicate that, in a defined, free-amino acid-containing
medium, BrnQ1 is required for iso-fatty acid synthesis, and Ile synthesis is sufficient to
maintain anteiso-fatty acid content in the absence of BCAA transport.
Table 3.4 Fatty acid profiles of S. aureus BCAA transporter mutants
% (wt/wt) of total fatty acida

Fatty
Acid
WT
SCFAs
BCFAs
Anteiso
Iso (Odd)
Iso (Even)

TSB
54 ±2
44 ±4
27 ±5
8 ±2
9 ±2

CDM
23 ±3
77 ±5
47 ±3
24 ±2
5 ±1

brnQ1brnQ2bcaP
TSB
52 ±2
48 ±2
33 ±4
6 ±2
10 ±1

CDM
11 ±4
88 ±5
88 ±5
<1.0
<1.0

brnQ1bcaP

brnQ1

bcaP

CDM
11 ±3
88 ±4
88 ±3
<1.0
<1.0

CDM
11 ±1
86 ±3
86 ±3
<1.0
<1.0

CDM
23 ±1
77 ±2
47 ±1
25 ±1
5 ±1

a

Values are the average percentage of fatty acids from three biological replicates ±SD. Fatty
acids less than 1% are not reported.

3.3.5

BrnQ1 and BcaP are required for growth in CDM at
temperatures below 37˚C

The adaptation of Gram-positive bacteria to growth at low temperature requires an increase
in anteiso-fatty acid content to increase membrane fluidity (15, 16, 47). We therefore
hypothesized that the brnQ1 mutant would be better adapted than the WT strain to growth at
lower temperatures since anteiso-fatty acids comprise 88% of membrane fatty acids in this
strain. In contrast to this hypothesis, the brnQ1 mutant exhibited growth attenuation relative
to the WT strain that was even more evident when grown at 25˚C compared to 37˚C (Figure
3.7A). This temperature-dependent growth phenotype was even more so evident with the
brnQ1-bcaP mutant (Figure 3.7A). Growth of the brnQ1-bcaP mutant could be restored
with expression of either brnQ1 or bcaP from a complementation vector (Figure 3.7B), or
addition of peptide source to the growth medium (Figure 3.7C). Since BcaP contributes to
this growth phenotype, but is not required for BCFA synthesis, we suspect this growthattenuated phenotype is independent of membrane content, yet nonetheless noteworthy.
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3.3.6

Staphyloxanthin abundance is increased in the membrane of
the brnQ1 mutant

In the course of our experiments as described above, we noticed that the cell pellet of the
brnQ1 mutant was brighter yellow than that of the WT strain when grown in CDM (Figure
3.8A). We therefore quantified the abundance of the pigmented carotenoid staphyloxanthin
in the membrane of the WT strain and brnQ1 and bcaP mutants. Indeed, the membrane of the
brnQ1 mutant contained more staphyloxanthin than either the WT strain or the bcaP mutant,
and this increase could be restored to WT levels upon complementation (Figure 3.8B,C).
Staphyloxanthin is a polar carotenoid that increases membrane rigidity (48), thus its presence
likely helps to counterbalance the high proportion of membrane fluidity-increasing anteisofatty acids in the brnQ1 mutant membrane (16). To determine if the presence of
staphyloxanthin masked the growth benefit of the brnQ1 mutant at low temperatures, we
obtained a mutant incapable of producing staphyloxanthin (crtM) and mobilized this
mutation into the brnQ1 mutant background to assess the ability of this strain to grow at low
temperatures. Staphyloxanthin did not alter growth of the brnQ1 mutant at 25˚C (Figure
3.8D), supporting our conclusion that this phenotype is not related to membrane BCFAs.
Staphyloxanthin is considered a virulence factor in S. aureus due to its antioxidant properties
which protect cells against oxidative stress, and its proposed role in resisting antimicrobial
peptides (42, 49, 50). We therefore investigated whether the brnQ1 mutant was more
resistant to these stressors. We found that the brnQ1 mutant was equally susceptible,
compared to the WT strain, to H2O2 (data not shown). The brnQ1 mutant and WT strain were
also equally susceptible to the membrane targeting antibiotics daptomycin and polymyxin B,
with MIC values in the range of those typically reported for S. aureus (Figure 3.8E,F) (51).
Altogether, these data indicate that although staphyloxanthin is more abundant in the brnQ1
mutant membrane, it is not sufficiently high to impart enhanced resistance to membrane
stressors.
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Figure 3.7 BCAA acquisition is required for growth in CDM at 25˚C
A,B) Strains were grown in complete CDM to mid-late exponential phase, sub-cultured to a
starting OD600 of 0.0025 in complete CDM and incubated at either 25˚C or 37˚C. C) Strains
were grown in CDM supplemented with 10 mg mL-1 of tryptone to mid-late exponential
phase and sub-cultured to a starting OD600 of 0.0025 in CDM 10 mg mL-1 of tryptone. Data
are the mean readable ODs of three biological replicates +/- SD.
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Figure 3.8 Staphyloxanthin abundance is increased in the brnQ1 mutant membrane
A) Cell pellets of cultures grown overnight in complete CDM. B,C) Staphyloxanthin was
extracted using warm methanol from the cell pellets of strains grown to log-phase in
complete CDM. Staphyloxanthin was quantified at an absorbance of 465 and expressed
relative to the OD600 of log-phase cultures. Data are the mean of three biological replicates
+/- SD and were analyzed using one-way ANOVA with the Tukey post test. * P ≤ 0.05, ** P
≤ 0.01, *** P ≤ 0.001. D) Cells were grown in complete CDM to mid-late exponential phase,
sub-cultured to a starting OD600 of 0.0025 in complete CDM and incubated at 25˚C. Data are
the mean of readable ODs of three biological replicates +/- SD. E,F) Strains were grown in
complete CDM to mid-late exponential phase and sub-cultured to a starting OD600 of 0.0025
in complete CDM containing serial dilutions of each antibiotics. The MIC was determined by
examining visible growth of two biological replicates after 24 h.
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3.3.7

BrnQ1 and BcaP are required for S. aureus infection and
colonization

High throughput studies have identified amino acid synthesis and transport genes as a major
category of genes required for S. aureus virulence (8, 9). These genes are also some of the
most up-regulated during growth in human nasal secretions (6). We therefore assessed the
contribution of Leu/Val transport to USA300 fitness in vivo using a murine systemic
infection model and nasal colonization model. Mice infected systemically with either the WT
strain or the single mutants lost approximately 20% of their body weight by day 4 of
infection and exhibited reduced activity and grooming. In contrast, mice infected with the
brnQ1-bcaP mutant lost on average approximately 5% of their body weight and appeared
active and well groomed (Figure 3.9A). Despite these apparent differences in disease
severity, we did not observe statistically significant differences in kidney bacterial burden
between mice in any of these groups (data not shown). We did, however, observe reduced
bacterial burden of the brnQ1 mutant and the brnQ1-bcaP mutant in the hearts (Figure 3.9B)
and there appeared to be a trend towards decreased CFUs in the liver for the brnQ1, bcaP,
and brnQ1-bcaP mutants (Figure 3.9C).
Using a nasal colonization model, we found that all mice inoculated with either the WT strain
or the brnQ1 or bcaP mutants remained colonized on day 7, with comparable CFUs
recovered. In contrast, the brnQ1-bcaP mutant could not be recovered on day 7 from 27%
(8/30) of mice (Figure 3.10). These data suggest that both BrnQ1 and BcaP are conditionally
required for fitness of S. aureus during nasal colonization.
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Figure 3.9 BCAA acquisition is required for full virulence of S. aureus in a murine
systemic infection model
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Balb/c mice were infected with 6-7 x 106 CFU of the WT strain (n=10), brnQ1 mutant (n =
8), bcaP mutant (n = 10), or brnQ1-bcaP mutant (n=11) via tail vein injection. A) Weight
loss was monitored every 24 hr post-infection. Data were analyzed for significance relative to
the WT strain using two-way ANOVA with the Dunnett’s post test. Mice were sacrificed on
day four of infection and B) hearts and C) livers were harvested and homogenized, and
dilutions were plated for CFU. The dotted line in panel B indicates the limit of detection. Log
transformed data were analyzed using one-way ANOVA with the Tukey post test. Data in
panel C are not significant. * P ≤ 0.05, *** P ≤ 0.001, **** P ≤ 0.0001.
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Figure 3.10 BCAA acquisition is required for S. aureus murine nasal colonization
C57BL/6 mice were treated with 2 mg mL-1 streptomycin sulfate in the drinking water 24 hr
prior to inoculation to remove the microbiota. Mice were intranasally inoculated with 1 x 108
CFU of the streptomycin resistant WT strain (n=25), brnQ1 mutant (n=12), bcaP mutant
(n=9), or brnQ1-bcaP mutant (n=30) under anesthesia. On day seven post-inoculation, mice
were sacrificed and snouts were excised, homogenized, and plated for CFU. The dotted line
indicates the limit of detection. Log transformed data were analyzed using one-way ANOVA
with the Tukey post test. ** P ≤ 0.01.
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3.4 Discussion
S. aureus requires BCAAs for several physiological processes, yet it does not readily
synthesize Leu or Val and rather relies on the acquisition of these nutrients to support its
metabolism (See Chapter 2). We previously identified BrnQ1 as a Leu/Val transporter,
however, a brnQ1 mutation was not sufficient to abolish Leu/Val transport (Figure 2.3).
Here, we identify BcaP as an additional Leu/Val transporter in S. aureus, which, when
mutated in combination with a brnQ1 mutation, results in abrogation of Leu transport and
almost a complete loss of Val transport. Identification of this additional, BcaP-dependent
mechanism of Leu/Val transport enabled us to characterize the consequence of Leu/Val
limitation on S. aureus physiology, and discern which transporters are required for growth,
membrane BCFA synthesis, and virulence. Our data indicate that although BrnQ1 is the
dominant transporter for supplying Leu and Val for growth and BCFA synthesis in vitro,
both BrnQ1 and BcaP contribute to S. aureus infection and colonization.
We attribute the minimal contribution of BcaP to S. aureus growth and BCFA synthesis in
vitro to its lower expression relative to BrnQ1. Although this was measured indirectly, this is
corroborated by the observation that over-expression of bcaP in the brnQ1-bcaP mutant is
sufficient to restore growth to WT levels. This finding contrasts BCAA transport in L. lactis
and B. subtilis, where BcaP serves as the more efficient transporter (32, 34). It should be
cautioned that the relative importance of BrnQ1 and BcaP in USA300 should not be
generalized across all S. aureus strains, since when expressed to similar levels off of a multicopy vector, BrnQ1 and BcaP in S. aureus exhibit comparable KM and Vmax values. Thus any
differences in transporter gene expression across strains would likely affect the relative
importance of BrnQ1 and BcaP.
Despite a contribution of BcaP to growth in CDM in the absence of BrnQ1, BcaP played no
role in supplying Leu and Val for BCFA biosynthesis. Instead, the cells replaced iso-fatty
acids with anteiso-fatty acids, presumably supported by Ile synthesis. This compensatory
mechanism is unique to S. aureus, as other Gram-positive bacteria, such as Bacillus subtilis
and Listeria monocytogenes, are able to synthesize all three BCAAs to maintain BCFA
content in the absence of exogenous BCAAs (15, 47, 52). Although the mechanism that
regulates this is currently unknown, it can be speculated that this ensures Leu and Val are
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conserved for protein synthesis, and might be one explanation as to why S. aureus has
retained Ile synthesis.
This study highlights a paradox in S. aureus, in which even upon Leu and Val starvation,
endogenous synthesis from the intact BCAA biosynthetic operon does not readily
compensate. Our data suggest that BCAA biosynthesis is eventually de-repressed following
an extended growth lag of the transporter mutants (14-18 hr) when either Leu or Val are
limited, a mechanism that is likely to involve known regulators of BCAA biosynthesis,
including CodY, CcpA, or YeaZ (25, 29, 45, 53, 54). Intriguingly, BCAA biosynthesis in the
transporter mutants grown in Val-limited conditions requires a compensatory mutation,
whereas a Leu-limited growth medium did not result in genetically-heritable suppressor
mutations. We had previously made a similar observation with WT USA300 grown in media
with either Val or Leu omitted; that is growth in media with Val omitted required a
compensatory mutation, whereas growth in media with Leu omitted did not (See Section
2.4). We are currently investigating the regulation of BCAA synthesis and why a
compensatory mutation is required for Val but not Leu synthesis.
Although BcaP plays a secondary role in growth in vitro, it has an additive function with
BrnQ1 in vivo. BcaP function might have been underappreciated in vitro due to differences in
growth conditions and/or gene expression. For example, the activation state of CodY in vivo
might differ from that in vitro, and it is possible that brnQ1 and bcaP expression respond
differently to the activation state of CodY (29, 46). Although both are CodY regulated, finetuning of expression could occur, and as such the requirement of each transporter would
depend on the availability of CodY effectors; BCAAs and GTP. Mechanisms of fine-tuning
BCAA transporter expression in B. subtilis include multiple upstream CodY binding sites
(55) and direct and indirect CodY regulation (56). Additionally, the affinity of CodY for each
promoter could determine the timing of expression in relation to nutrient availability (57). A
more detailed characterization of the regulation of these genes might provide insight as to
how these genes are regulated in vivo.
The systemic infection model revealed that infection with a strain with mutations in both
brnQ1 and bcaP not only resulted in reduced bacterial burden in the heart, but also in
significantly less weight loss and disease severity. The ability of this strain to reach such a
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high bacterial burden in the kidneys (e.g. 108 CFU, data not shown) but not cause signs of
disease could be the result of altered toxin secretion in vivo, and will need to be explored in
future studies. The ability of the brnQ1 and brnQ1-bcaP mutants to replicate efficiently in
some organs (e.g. livers and kidneys) and not others (e.g. heart) could reflect differences in
nutrient availability (e.g., peptides sources and/or host-derived fatty acids). Indeed, S. aureus
encodes a di/tri-peptide permease (dtpT) and several oligo-peptide permeases that might
supply BCAAs in vivo (58), although the requirement for oligopeptide transport for S. aureus
virulence is not known. Moreover, S. aureus is able to incorporate host-derived fatty acids in
its membrane (59) and, when grown in serum, BCFAs comprise less than 40% of membrane
fatty acids in USA300 (60). Finally, although both brnQ1 and bcaP are up-regulated in
human serum and blood, so are the genes for BCAA biosynthesis (10). Thus it is possible
that Leu and Val are synthesized in vivo.
Our data suggest a dichotomy in the ability of the brnQ1-bcaP mutant to colonize murine
nares, as the brnQ1-bcaP mutant was not recovered from several mice on day 7, yet in some
mice was recovered at CFUs comparable to the WT strain. At this point it is unclear whether
this is a result of the inability of the brnQ1-bcaP mutant to establish colonization in some
circumstances, or perhaps it is cleared at a more rapid rate, albeit asynchronously, than the
WT strain. We hypothesize the former; cells must maintain a threshold level of BCAAs to
support growth in this environment, and BCAA transport is essential to do so. Free amino
acid transport might be critical in this environment due to limited availability of peptide
sources of BCAAs. The finding by Krismer et al., that an S. aureus strain incapable of
synthesizing Met has a reduced capacity for nasal colonization suggests that peptides are not
sufficient to complement amino acid deficiency in this environment (6). With limited
availability of peptides, the transporter mutant must rely on BCAA biosynthesis for growth.
Although the BCAA biosynthesis genes are up-regulated when S. aureus is grown in media
that mimics human nasal secretions (6), the biosynthetic enzymes require iron (61), which is
likely limited in this environment (62). Thus, in the absence of transport, cells will only be
viable if there is sufficient iron and/or carbon to support BCAA synthesis. The variability in
nutrient levels across mice might be sufficient to create this threshold for growth. More
studies will be required to test this hypothesis.
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Altogether, this study provides a detailed characterization of the role of BCAA transport in S.
aureus general physiology, and lays a foundation for understanding the link between BCAA
metabolism and virulence in S. aureus.
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Chapter 4

4

Regulators of BCAA synthesis in S. aureus

4.1 Introduction
Staphylococcus aureus is a serious human pathogen capable of causing infections that range
from mild skin and soft tissue infections, to severe infections of the bone, muscle, heart and
lung (1–4). To survive and thrive in such diverse host environments, S. aureus must maintain
sufficient levels of metabolites and co-factors to support virulence determinant production
and replication (5, 6). The branched-chain amino acids (BCAAs; Ile, Leu, Val) represent an
important group of nutrients for S. aureus metabolism and virulence, as they are required for
protein synthesis and synthesis of membrane branched-chain fatty acids (BCFAs), which are
important for S. aureus environmental adaptation. Indeed, both BCAA biosynthesis (7–11)
and transport (12–15) have been linked to promoting the virulence of pathogens in various
host environments. In addition to their nutritional importance, the BCAAs are key regulatory
molecules in low GC Gram-positive bacteria, as they are effectors of the global
transcriptional regulator CodY. CodY coordinates expression of nutrient scavenging and
synthesis systems, as well as virulence genes, upon depletion of both BCAAs and GTP (16–
22). The requirement of BCAAs for both S. aureus replication and niche adaptation
necessitates that it either synthesize these nutrients or acquire them from the environment.
Bacteria acquire BCAAs via dedicated active transporters, including BrnQ (Gram-negative
and –positive bacteria), BcaP (Gram-positive bacteria), and the high affinity ATP-Binding
Cassette (ABC) transporter LIV-I (Gram-negative bacteria) (23). S. aureus encodes three
BrnQ homologs (BrnQ1, BrnQ2, BrnQ3), and BcaP. BrnQ1 and BcaP transport all three
BCAAs, with BrnQ1 playing a predominant role, and BrnQ2 is an Ile-dedicated transporter
(Chapters 2 and 3). Little/no BCAA transport function is associated with BrnQ3 (Chapter 2).
Despite encoding the BCAA biosynthetic operon, S. aureus relies on the acquisition of
BCAAs, most importantly Leu and Val, for rapid growth in media with excess or limiting
concentrations of BCAAs, indicating that BCAA biosynthesis is typically repressed
(Chapters 2 and 3). Paradoxically, biosynthesis remains repressed even in the absence of an
exogenous source of Leu or Val, with growth of S. aureus observed only after a prolonged
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period of 24 h and 48 h respectively (Figure 4.1), which is why previous studies have been
misled to conclude that S. aureus is auxotrophic for Leu and Val (24, 25). The molecular
explanation for this in S. aureus has remained elusive.
Both Gram-positive and Gram-negative bacteria repress BCAA biosynthesis when
intracellular levels are sufficient to support growth. In the Gram-negative organisms, E. coli
and S. typhimirium, this is regulated by attenuation, which couples translation of a BCAArich peptide upstream of the biosynthetic genes with transcriptional read-through (26–31). In
Gram-positives, this is mediated by CodY-dependent repression of the biosynthetic genes
(17, 18, 32–35). Additional layers of regulation have also been described in the Grampositive bacterium B. subtilis where, in addition to CodY regulation, the ilv-leu operon is
regulated by global regulators that coordinate expression of the operon in response to carbon
(CcpA) and nitrogen (TnrA) (36). Additional fine-turning of ilv-leu expression is mediated
by a Leu-responsive T-box riboswitch (36–39), as well as mRNA processing (40).
The BCAA biosynthetic genes in S. aureus, encoded by the ilvDBNleuABCDilvA operon and
ilvE, are similarly repressed by CodY, which binds to two regions upstream of ilvD proximal
to the transcriptional start site and two regions within the operon, preceding ilvC and leuC
(Figure 4.1) (16–18). Repression is also mediated by the essential genes gcp and yeaZ
through an unknown mechanism (41, 42). Yet even with this knowledge, the growth
phenotype of S. aureus in the absence of Leu or Val remains unaccountable. We therefore
investigated the mechanisms governing these phenotypes in S. aureus to resolve this and to
identify the signals required to induce synthesis. We identify a CodY-dependent and independent mechanism of repression and identify the corresponding metabolic cues
regulating each mechanism, therefore revealing how S. aureus regulates its preference for
exogenous BCAAs and the environments where endogenous synthesis is induced.

121

Figure 4.1 Organization of the ilv-leu operon in S. aureus.
Biosynthetic pathway of BCAA biosynthesis in S. aureus and the genomic context of the
biosynthetic genes in the USA300 FPR3757 genome.
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4.2 Materials and Methods
4.2.1

Growth conditions and plasmid construction

All strains and plasmids used in this study are described in Table 4.1. Methicillin-resistant S.
aureus (MRSA) isolated pulsed-field gel electrophoresis type USA300 LAC that has been
cured of the erythromycin resistance plasmid was used in all experiments as the wild-type
(WT) strain. S. aureus strains were grown in either tryptic soy broth (TSB) (EMD Millipore,
Billerica, MA) or in a chemically defined medium (CDM), described previously (See Section
2.2.1). Final concentrations of Ile, Leu and Val in complete CDM were 228 M, 684 M,
and 684 M, respectively. Final concentrations were adjusted to 10% of their concentration
in complete CDM in some experiments, as indicated. For growth experiments in TSB, S.
aureus strains were pre-cultured in TSB until mid-exponential phase was reached, and then
sub-cultured into fresh TSB to a starting OD600 of 0.01. For growth experiments in CDM, S.
aureus strains were pre-cultured in CDM until mid-exponential phase was reached, and then
sub-cultured into fresh CDM to a starting OD600 of 0.05 in either complete CDM or CDM
where BCAA concentrations were limited or omitted, as indicated. Growth curves were
performed in 100-well plates containing 200 L/well of media and were read using the
Bioscreen C visible spectrophotometer (Growth Curves USA; Piscataway, NJ). End point
growth assays were performed in tubes with a 7:1 tube:volume ratio. All growth experiments
were performed at 37˚C with shaking. Growth media were supplemented with
chloramphenicol (10 g mL-1), ampicillin (100 g mL-1), or erythromycin (3 g mL-1), where
required.

4.2.2

Mutagenesis and construction of plasmids

Deletion of bcaP was constructed using the pKOR-1 plasmid as described in Chapter 2.
Primer sequences were based on the published USA300 FPR3757 genome and are displayed
in Table 4.2. The bcaP deletion was introduced into the markerless brnQ1 deletion mutant,
described previously (See Section 2.2.2). The pGYlux vectors were constructed using
primers described in Table 4.2. lux plasmids were further used as templates for site-directed
mutagenesis, using primers described in Table 4.2. Briefly, PCR reactions containing the
Phusion ® High-Fidelity DNA Polymerase (ThermoFisher, Waltham, MA) were set up such
that half of the reaction mixture contained the forward primer and the remaining half
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contained the reverse primer. These reactions proceeded for 3 cycles of 98˚C for 10 s, 60˚C
for 30 s, and 72˚C for 12 min. After 3 cycles, the forward and reverse primer reactions were
mixed together and the reactions proceeded for an additional 17 cycles. Plasmids were
treated with DpnI (New England Biolabs, Ipswich MA) for 1 hr at 37˚C and were then
transformed into E. coli DH5. Mutations were confirmed by PCR. All plasmids were first
constructed in E. coli DH5 and subsequently electroporated into the restriction-defective S.
aureus strain, RN4220, prior to electroporation into the desired strain.

4.2.3

Selection for ValS mutants and whole genome sequencing

To select for genetic mutations that permit adaptation to growth in media lacking Val, twelve
independent colonies of WT S. aureus were grown in complete CDM to mid-exponential
phase and sub-cultured into CDM lacking Val. Cells that grew were harvested and plated
onto TSB agar and grown overnight at 37˚C. Isolated colonies were grown in complete CDM
to mid-exponential phase and sub-cultured into CDM lacking Val to confirm the occurrence
of a heritable mutation. Genomic DNA was isolated from all twelve mutants, referred to as
ValS-mutants, as well as from two biological replicates of our laboratory WT USA300, using
the Invitrogen PureLink™ Genomic DNA Preparation Kit (ThermoFisher Scientific, Boston
MA) per the manufacturer’s instructions. Primers used for the targeting sequencing of the
region upstream of ilvD and the codY gene are listed in Table 4.2. Samples were sent to the
London Regional Genomics Center for sequencing on the MiSeq platform. Libraries were
prepared using the Nextera™ XT DNA Library Preparation kit (Illumina, San Diego, CA).
150 bp reads were mapped to the USA300 FPR3757 (NC_007793.1) genome using the
BWA-MEM aligner (43) and variants were determined using SAMtools (44).
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Table 4.1 Strains and plasmids
Strain or Plasmid
Strains
S. aureus
USA300
RN4220
H3001
H2568
H2563
H3386
H3584
E. coli
DH5

Plasmids
pRMC2
pcodY
pGYlux
pGYilvDWT::lux
pGYilvDValS1::lux
pGYilvDValS7::lux
pGYilvDValS9::lux
pGYilvDP::lux
pGYilvDC::lux

a

Descriptiona

Source or
reference

USA300 LAC cured of antibiotic resistance
plasmid
rK- mK+; capable of accepting foreign DNA
USA300 codY::N; EmR
USA300 brnQ1
USA300 brnQ2
USA300 bcaP
USA300 brnQ1bcaP

(45)

F- 80dlacZM15 recA1 endA1 gyrA96 thi-1
hsdR17(rK- mK-) supE44 relA1 deoR (lacZyAargF)U169 phoA

Promega

Anhydrotetracycline-inducible expression vector;
ApR in E. coli; Cmr in S. aureus
pRMC2 containing codY; CmR
Vector harboring promoterless luxABCDE operon;
CmR
Lux reporter vector with ilvD promoter from WT
USA300; CmR
Lux reporter vector with ilvD promoter mutated to
contain the ValS-1 SNP; CmR
Lux reporter vector with ilvD promoter mutated to
contain the ValS-7 SNP; CmR
Lux reporter vector with ilvD promoter mutated to
contain the ValS-9 SNP; CmR
Lux reporter vector with only the CodY binding
motifs in the ilvD promoter; CmR
Lux reporter vector with the ilvD promoter from
WT USA300; CmR

(48)

(46)
(47)
Chapter 2
Chapter 2
This study
This study

This study
(49)
This study
This study
This study
This study
This study
This study

Abbreviations: EmR, ApR, CmR, designate resistance to erythromycin, ampicillin and

chloramphenicol respectively.
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Table 4.2 Oligonucleotides used in this study.
Oligonucleotides a
bcaP Ups F
bcaP Ups R

GGGGACAAGTTTGTACAAAAAAGCAGGCTCAGTCTTCGTAT
TCACCTGC
CTTCCCATAAACTTTCCTCC
For generating upstream arm for bcaP deletion

bcaP Dwn F
bcaP Dwn R

5’ /Phos/ ACGTAGCTGAATACCACCC
GGGGACCACTTTGTACAAGAAAGCTGGGTTGTACCTGCTGA
CGAAGTAG
For generating downstream arm for bcaP deletion

ilvDC F
ilvDC R

GATCCCCGGGACCTGCTCCTAAATCTCCG
GATCGTCGACACTTCTTGCTGGTGCTTGG
For cloning ilvD 5’UTR into pGYlux

ilvDP F
ilvDPR

GATCCCCGGGGTACGTCTTACACCAAG
GATCGTCGACAGTTGTCGGTTGATGTTC
For cloning partial ilvD 5’UTR into pGYlux

ilvDValS-1 F
ilvDValS-1 R

CAA ATA TTA TTA TTT TAT aAT ACT CTT TAG GAC TCG
CGA GTC CTA AAG AGT ATt ATA AAA TAA TAA TAT TTG
For site directed mutagenesis of pGYlux::ilvD

ilvDValS-7 F
ilvDValS-7 R

CTA AAC GCT TTA AGT CaT ATT TCT GTT TGA ATG
CAT TCA AAC AGA AAT AtG ACT TAA AGC GTT TAG
For site directed mutagenesis of pGYlux::ilvD

ilvDValS-9 F
ilvDValS-9 R

CTA AAC GCT TTA AGc CCT ATT TCT GTT TG
CAA ACA GAA ATA GGg CTT AAA GCG TTT AG
For site directed mutagenesis of pGYlux::ilvD

codY F
codY R

GATCGGTACCCCGAATGCAGTTGTAGATATTACC
GATCGAGGCTCTTATGTCCCAGACTCATCGAC
For cloning codY into pRMC2

codY Seq F
codY Seq R

GCAATTACTCGCTTAGCTGAG
GTGTGTATTGGCTTTATAGCCG
For target directed sequencing of codY

ilvD qPCR F
ilvD qPCR R

GCTATCTTTTGCTCTGGTGG
AGGGCAGGCATTTTGTTCC
For qPCR of ilvD

ilvC qPCR F
ilvC qPCR R

CAAGATGTAAAAACGGACGC
GTCAAAAGAACGACCTGGG
For qPCR of ilvC
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a

All primer sequences are based on the USA300 FPR3757 genome; restriction sites are
underlined; nucleotide mutated in site directed mutagenesis is indicate in lower case.

4.2.4

TCA precipitation of proteins and SDS-PAGE

Strains were pre-grown in TSB to mid-exponential phase and then sub-cultured into TSB to a
starting OD600 of 0.01 and grown overnight. Optical densities (OD600) of stationary phase
cultures were determined and a supernatant volume equivalent to 5 OD units was harvested
and incubated with tricholoracetic acid (TCA) (Sigma-Aldrich, St. Louis, MO) at a final
concentration of 20% overnight at 4˚C. Precipitated protein samples were run on a 12%
acrylamide gel and stained with Coomassie-Blue.

4.2.5

lux reporter assays

Kinetic lux reporter experiments were performed in flat, clear-bottom 96-well white plates
(Thermo Fisher Scientific) and read using a BioTek Synergy™ H4 Hybrid Multi-Mode
Microplate Reader (BioTek Instruments Inc, Winooski, VT). Pre-cultures were inoculated
into either complete or limited CDM to a starting OD600 of 0.01 in 200 L/well.
Luminescence and OD600 values were read at hourly intervals. For end-point lux reporter
experiments, pre-cultures were sub-cultured into either complete or limited CDM to a
starting OD600 of 0.05 in tubes with a 7:1 tube:volume ratio. At hourly intervals, aliquots of
200 L were transferred to flat, clear-bottom 96-well white plates (Thermo Fisher Scientific)
and luminescence and OD600 values were read. Samples of strains containing the lux
construct with the complete ilvD promoter region were supplemented with 0.1% (vol/vol)
decanal in 40% ethanol and luminescence was measured immediately. Data presented are the
relative light unit (RLU) values normalized to the OD600 of the sample when the cultures
reached mid-exponential phase (OD600 0.6-0.8).
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4.2.6

RT-qPCR

RNA was isolated from cells grown to mid-exponential phase (OD600 of 0.6-0.8) in complete
CDM using the Aurum Total RNA Mini Kit (Bio-Rad; Hercules, CA) per the manufacturer’s
instructions. RNA (500 ng) was reverse transcribed using SuperScript II (Invitrogen,
Carlsbad, CA) per the manufacturer’s instructions using 500 g mL-1 of random hexamers.
cDNA was PCR-amplified using SensiFAST™ SYBR® No-ROX Kit (Bioline, Taunton,
MA). Data were normalized to expression of the rpoB reference gene. Primers used are listed
in Table 4.2.

4.2.7

Bioinformatics

Putative terminator structures in the ilvD 5’UTR were identified using the predictive software
RibEx and RNAfold. Mfold was used to identify putative antiterminator sequences. RNAfold
and Mfold were used to predict Class 1 and Class 2 T-box Stem 1 features. Multiple
sequence alignments of T-box sequences were conducted with all known T-box sequences in
S. aureus subsp. aureus N315 (NC_002745.2) and aligned with the ilvB T-box from B.
subtilis (NC_000964.3) and predicted Clostridium spp. ilvB T-box (NC_001898.1). The ilvD
5’UTR from USA300 FPR3757 was aligned to 168 S. aureus complete genomes using
BLAST (see Appendix A).
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4.3 Results
4.3.1

Growth adaptation of S. aureus to BCAA deprivation

S. aureus has previously been reported as auxotrophic for Leu and Val (24, 25), despite
possessing an intact BCAA biosynthetic operon. We therefore followed up on these reports
in an attempt to understand the molecular basis for this observation. Indeed, we observed no
growth of S. aureus after 12 hr of growth in media lacking either Leu or Val (Figure 4.2A).
However, prolonged incubation allowed us to observe growth in media lacking Leu after 1016 hr and growth in media lacking Val after 24-36 hr (Figure 4.2A) and (Figure 2.9). The
extended growth lag led us to question whether these conditions select for mutations that
result in adaptation to the absence of exogenous Leu or Val. To test this, we took cells having
grown in media lacking either Leu or Val, and subcultured them back into the same medium
from which they were recovered. Cells recovered from CDM-Leu medium exhibited the same
growth delay upon sub-culture into the same medium, indicating that these cells had not
acquired a heritable mutation. When we recovered cells from CDM-Val medium, plated them,
and then repeated the experiment, we found that upon sub-culture, they grew readily,
suggesting that they were synthesizing Val (ValS) (Figure 4.2B). These results suggest that
growth in the absence of exogenous Leu requires a regulatory adaptation, whereas growth in
the absence of Val selects for a heritable mutation. We hypothesized that identification of the
genetic mutations permitting growth of S. aureus in the absence of exogenous Val would
reveal important regulators of the BCAA biosynthetic operon.
CodY is a known repressor of the BCAA biosynthetic operon in S. aureus and binds to two
regions upstream of ilvD proximal to the transcriptional start site and two regions within the
operon, preceding ilvC and leuC (16–18) (Figure 4.1). To confirm its role in regulating
BCAA biosynthesis in USA300, we evaluated the growth of a codY mutant in CDM lacking
each individual BCAA. The codY mutant did not have a growth defect in any of the BCAA
depleted media, indicating that endogenous synthesis, uncoupled from CodY repression, is
sufficient to support growth in the absence of an exogenous source in this strain (Figure
4.2C).
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Figure 4.2 Growth adaptation of S. aureus to BCAA depletion
A) WT USA300 was pre-grown in complete CDM to mid-exponential phase and then subcultured into either complete CDM or CDM with BCAAs omitted, as indicated. B) Cells
recovered from the CDM with no Val in panel A were plated. A single colony was selected
(ValS) and subjected to growth in complete CDM and CDM with no Val (filled symbols).
Growth was compared to the parental WT strain (open symbols) in the same conditions. C)
The codY mutant was pre-grown in complete CDM to mid-exponential phase, and then subcultured into either complete CDM or CDM with BCAAs omitted, as indicated. Data are the
mean +/- SD of three biological replicates.
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4.3.2

Growth in media lacking Val selects for mutations in codY

Since a codY mutant synthesizes BCAAs, we next investigated whether growing WT S.
aureus in the absence of Val selects for mutations in codY. To do this, we isolated mutants
from twelve independent cultures of the WT strain in media lacking Val (referred to as ValS
mutants) and amplified the codY gene. Five of the twelve mutants contained mutations in
codY; one had a point mutation resulting in a premature stop codon, two had a 60 bp deletion,
and two had independent point mutations resulting in nonsynonymous mutations (Figure
4.3A). We mapped the mutations to the CodY structure to identify their localization in the
protein (PDB ID:5EY0) (50). All mutations occur in the linker region between the metabolite
sensing domain and the DNA-binding domain Figure 4.1B.
Table 4.3 Mutations identified in CodY
Mutants
ValS-2
ValS-3
ValS-4
ValS-8
ValS-10
a

Positiona
1260149-1260208
1260119
1260149-1260208
1260188
1260230

Mutation
∆Arg167-Ala186
Glu157 to Stop
∆Arg167-Ala186
Ser180 to Pro
Leu194 to Phe

Position in the USA300 FPR3757 genome (NC_007793.1)

To confirm that these mutations result in an inactive CodY protein, we assessed the secreted
protein profile of these mutants, as CodY represses several secreted proteins (51) and
therefore the secreted protein profile of a codY mutant differs substantially from WT. The
secreted protein profiles of the ValS mutants with confirmed mutations in codY resembled the
protein profile of the codY mutant, except for ValS-10 mutant (Figure 4.3C), indicating that
all but one of our codY mutations result in an inactive CodY protein. Complementation of all
ValS mutants with confirmed codY mutations with a copy of the codY gene in trans reverted
the growth phenotypes of theses mutants in media lacking Val to WT (Figure 4.3D),
confirming that mutations in CodY enable Val synthesis.
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Figure 4.3 The absence of exogenous valine selects for mutations that inactivate CodY.
A) Schematic representation of the mutations identified in CodY. B) Mutations identified are
indicated on the CodY structure (PDB ID:5EY0) in yellow, except for the Ser180 to Pro
mutation, which is indicated in green. CodY ligands, Ile and GTP, are coloured based on
atomic composition. C) Strains were pre-grown in TSB to mid-exponential phase, then subcultured into TSB for 16 hr. Supernatants were collected and proteins were precipitated using
TCA. Protein samples were normalized to the equivalent of 5 ODs and run on a 12% SDSPAGE gel. D) Strains were pre-grown in complete CDM to mix-exponential phase, then subcultured into either complete CDM or CDM with Val omitted. OD600nm was read after 16 hr
of growth. Data are the mean +/- SD of three biological replicates.
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4.3.3

Growth in media lacking Val selects for mutations in the 5’UTR
of ilvD

We next investigated whether the secreted protein profiles of the remaining seven ValS
mutants, which were confirmed to not have mutations in the codY gene, were altered to rule
out mutations that might indirectly affect the ability of CodY to regulate the ilv-leu operon
(i.e. mutations in GTP synthesis). The protein profiles of the seven mutants resembled the
WT strain (Figure 4.4), suggesting the mutations affect a CodY-independent mechanism of
regulation. We sequenced the region upstream of the first gene in the ilv-leu operon, ilvD,
reasoning that mutations might occur in the binding sequence of transcriptional regulators.
This approach revealed that all seven of these ValS mutants had mutations in the 5’UTR of
ilvD, with a total of three unique point mutations and one 27 bp deletion (Table 4.4) and
(Figure 4.5A).
Table 4.4 Mutations identified in the 5’ UTR of ilvD
Mutants

Positiona

ValS-1
ValS-5
ValS-6
ValS-7
ValS-9
ValS-11
ValS-12

2164689
2164762-2164788
2164762-2164788
2164741
2164739
2164762-2164788
2164739

a

No. of bp upstream
of ilvD start codon
184
85
85
132
134
85
134

Mutation
T -> A
27 bp deletion
27 bp deletion
C -> A
T -> C
27 bp deletion
T -> C

Position in the USA300 FPR3757 genome (NC_007793.1)

In order to conclude that these mutations were the single basis for the observed ability of the
mutants to grow without delay in media lacking Val, we sequenced the genomes of the
mutants and the parent USA300 strain. This indeed confirmed these mutations to be the
single difference between the mutants and the parental strain. To confirm that mutations in
the 5’UTR of ilvD result in an increase in expression of the ilv-leu operon, we generated a
luminescence reporter of the ilvD promoter region by cloning the 5’UTR of ilvD into the
pGY::lux vector, and subsequently mutated the 5’UTR to contain each of the point mutations
identified. All three mutant sequences resulted in an increase in ilvD promoter activity
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Figure 4.4 Secreted protein profiles of ValS-mutants with WT codY sequence
Strains were pre-grown in TSB to mid-exponential phase, then sub-cultured into TSB for 16
hr. Supernatants were collected and proteins were precipitated using TCA. Protein samples
were normalized to the equivalent of 5 ODs and run on a 12% SDS-PAGE gel.
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Figure 4.5 Mutations in the ilvD 5’UTR result in an increase in promoter activity and
ilv-leu operon expression
A) Schematic representation of mutations identified in the ilvD 5’UTR. B) WT USA300 with
the pGY::lux plasmid, containing either the WT or mutant ilvD promoter region, was grown
in complete CDM to mid-exponential phase and then sub-cultured into complete CDM.
Luminescence was read at mid-exponential phase and normalized to the OD600nm. Data are
the mean +/- SD of three biological replicates. C,D) Strains were grown in complete CDM to
mid-exponential phase and then sub-cultured into complete CDM. Cells were harvested at
mid-exponential phase and RNA was isolated. Expression of ilvD and ilvC was normalized to
expression of rpoB. Data are the mean +/- SD of three biological replicates.
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(Figure 4.5B). Furthermore, we selected two of the mutants, ValS-1 (SNP) and ValS-5
(deletion) and measured expression of ilvD and ilvC in the ilv-leu operon, and found that both
genes were up-regulated in the mutant strains compared to the WT strain (Figure 4.5C,D).

4.3.4

Exogenous BCAAs differentially regulate the ilv operon

Although in vitro studies (i.e. EMSAs and DNAase footprinting studies) of CodY suggest
that all three BCAAs increase its DNA binding activity (22, 52, 53), our results call in to
question the relative importance of each BCAA for regulating CodY activity in vivo (i.e.
during growth). That is to say, if Val was an important effector of CodY, removal of Val
from the growth medium would result in a decrease in CodY activity and subsequently derepression of the ILV operon. Instead, we observe that this condition selects for a mutation
producing a null CodY protein. This indicated to us that perhaps each individual BCAA does
not affect CodY equally during growth. We therefore used the promoter:reporter system to
investigate CodY regulation of the ilvD expression. To study CodY-dependent promoter
activity in isolation of putative regulatory elements in the ilvD 5’UTR, we generated two
reporter constructs; one containing the complete ilvD leader region, including both the CodY
binding sequences and the putative regulatory element (pGYilvDC::lux), and one containing a
partial ilvD leader, including only the CodY binding sequence (pGYilvDP::lux) (Figure
4.6A). We first confirmed that both constructs responded to CodY and, indeed observed
higher promoter activity in the codY mutant compared to the WT strain that peaked during
mid-exponential growth (Figure 4.6B,C). All endpoint pGY::lux experiments from this point
on are therefore the luminescence normalized to the optical density of mid-exponential phase
cells (RLU/OD600).
We next assessed promoter activity in response to depletion of each BCAA. Since complete
omission of Leu and Val from the growth medium significantly attenuates S. aureus growth,
we instead limited their concentrations to 10% of that in complete CDM to minimize
differences in growth. ilvD promoter activity of the pGYilvDP::lux construct increased to
levels comparable to the codY mutant only upon Ile limitation, and limitation of Leu or Val
in combination with Ile did not alter ilvD promoter activity any further (Figure 4.7A). ilvD
promoter activity of the pGYilvDC::lux construct also increased upon Ile limitation, yet in
contrast to the pGYilvDP::lux plasmid, we observed a further increase in promoter activity
upon limitation of both Ile and Leu (Figure 4.7B). These data suggest that Ile is the
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predominant BCAA to affect CodY activity, at least on the ilvD promoter region, and Leu
contributes to ilvD promoter activity via the 5’UTR regulatory element. To test CodY
activity under conditions where cells are not nutrient deprived, we also assessed promoter
activity of the pGYilvDP::lux construct in media containing excess amounts of each BCAA,
expecting a repressive effect on CodY activity. Indeed, we found that whereas excess
amounts of Ile in the growth medium repressed ilvD promoter activity (Figure 4.7C), Leu had
no effect (Figure 4.7D), and intriguingly, excess Val had the opposite effect of increasing
promoter activity (Figure 4.7E). We further confirmed a predominant role for Ile in
regulating CodY activity on the brnQ1 promoter region as well (Figure 4.7F-H), suggesting
that Ile is the predominant BCAA to regulate CodY activity on its other target genes.
We previously identified mechanisms of BCAA transport in S. aureus, including BrnQ1 and
BcaP, which transport Ile, Leu and Val, and BrnQ2, a dedicated Ile transporter (Chapter 2
and 3). We therefore assessed ilvD promoter activity in strains mutated in these transporters
to observe the contribution of each transporter to either CodY-dependent or CodYindependent regulation of BCAA biosynthesis. ilvD promoter activity of the pGYilvDP::lux
construct increased only in the brnQ2 mutant (Figure 4.8A), whereas the pGYilvDC::lux
increased in the brnQ1 and brnQ1bcaP mutants (Figure 4.8B). These data indicate that
BrnQ2-dependent Ile transport is linked to CodY activity and BrnQ1/BcaP-dependent Leu
transport is linked to the 5’UTR regulatory element. Notably, using the complete 5’UTR, we
did not observe a change in promoter activity in the brnQ2 mutant. We have previously
shown that brnQ1 is up-regulated in a brnQ2 mutant and consequently a brnQ2 mutant takes
up more Leu and Val permitting enhanced growth in media limited for these amino acids
(Figure 2.11). We thus postulate that in a brnQ2 mutant, the increased Leu uptake causes
repression of ilvD promoter activity via the regulatory element and overrides the CodYdependent Ile response.
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Figure 4.6 Construction of the ilvD promoter:reporter vectors.
A) Diagram of the promoter regions cloned into the pGY::lux vector to generate the partial
promoter construct (pGYilvDP::lux) and the complete promoter construct (pGYilvDC::lux).
B,C) Strains were pre-grown in complete CDM to mid-exponential phase and then subcultured into complete CDM in a 96-well plate. Luminescence (left axis, filled shapes) and
OD600nm (right axis, open shapes) were read hourly. Data are the mean +/- SD of three
biological replicates.
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Figure 4.7 Ile is the predominant BCAA to regulate CodY activity on select CodY
target promoters
A,B) Strains were pre-grown in complete CDM to mid-exponential phase and then subcultured into either complete CDM or CDM with limiting concentrations of BCAAs, as
indicated. Luminescence values were read when cells reached mid-exponential phase and
normalized to the OD600nm. C-E) WT USA300 possessing the lux vector containing only the
CodY binding site of the ilvD promoter (pGYilvDP::lux) or containing the CodY binding site
from the brnQ1 promoter (pGYbrnQ1::lux) was grown in complete CDM to mid-exponential
phase and then sub-cultured into complete CDM in a 96-well plate. Luminescence (left axis,
open shapes) and OD600nm (right axis, filled shapes) were read hourly. Data are the mean +/SD of three biological replicates.
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Figure 4.8 BCAA transporters link exogenous BCAAs to regulation of BCAA synthesis
S. aureus strains possessing either the lux vector containing the partial ilvD promoter
(pGYilvDP::lux) or the complete ilvD promoter (pGYilvDC::lux) were pre-grown in complete
CDM to mid-exponential phase and then sub-cultured into complete CDM. Luminescence
values were read when cells reach mid-exponential phase and were normalized to the
OD600nm. Data are the mean of three biological replicates +/- SD.
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4.3.5

Identification of an attenuator and terminator in the 5’UTR of
ilvD

We next analyzed the 5’UTR of ilvD for putative structural elements that could dictate the
regulatory mechanism, which responds to Leu. We initially considered that the 5’UTR might
function as a T-box riboswitch, since the ilv-leu operon in B. subtilis is regulated by a
tRNALeu-responsive T-box riboswitch (37, 39). Predictive structure analysis and sequence
comparison of the ilvD 5’UTR to other known T-box sequences revealed that although the S.
aureus ilvD T-box contains features that resemble other T-boxes (Figure 4.9), the variability
in the distal loop and long insertions between features are not consistent with Class 1 or 2
Stem 1 structures essential to T-box function (54). We next considered translation-dependent
transcriptional regulation (i.e. attenuation), since BCAA-rich leader peptides have been
found to regulate BCAA biosynthetic genes in E. coli (29), S. typhimurium (30, 31), and are
predicted to regulate BCAA synthesis in L. lactis sp. lactis (55), C. glutamicum (56, 57), and
Streptococcus spp. (58). A search for ORFs in the ilvD leader sequence revealed a 26 amino
acid peptide that contains a string of three Ile codons followed by two Leu codons, and an
additional three interspersed Leu codons (Figure 4.10). A ribosome binding site was also
identified 9 bp upstream of the start codon. We also identified a terminator hairpin structure
consistent with transcription termination (Figure 4.10). We therefore predict that, in S.
aureus, Leu deprivation is sensed via attenuation.
We next considered how the mutations we selected for in media lacking Val might disrupt
these features. Intriguingly, the 27 bp deletion in ValS-5/6/11 deletes the predicted terminator
stem-loop (Table 4.5), supporting that this is a biologically relevant structure, and the T153A
mutation (ValS-1) changes a Leu codon in the leader peptide to a stop codon (Table 4.5). The
T203C (ValS-9/12) and C205A (ValS-7) mutations occur in a region where we would predict
the anti-terminator to form. If our model is correct, these mutations likely destabilize the
terminator formation, leading to transcriptional read-through.
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Figure 4.9 Nucleotide sequence alignment of ilvD 5’UTR with known T-box
riboswitches
Sequences of all annotated S. aureus T-boxes (based on the S. aureus subsp. aureus N315
genome NC_002745.2), the B. subtilis ilvB T-box (NC_000964.3) and predicted Clostridium
spp. ilvB T-box (NC_001898.1), labelled by regulated gene, were analyzed. Key features
analyzed include the GA Motif (GA); E-loop (AGUA-box), the AG Bulge (AGVGA-box),
Distal Loop (GNUG-box); and the Specifier Loop (GAA...XXXA) where XXX represents
the tRNA codon.
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Figure 4.10 Attenuator features in the 5’UTR of ilvD
Sequence analysis of the 5’UTR of ilvD revealed a sequence consistent with a terminator
hairpin i.e. stem (highlighted in blue), loop (highlighted in red), followed by a poly-U tail. A
putative open reading frame (ORF) containing multiple Ile and Leu codons was also
identified. Both features occur downstream of the transcriptional start site (arrow).
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Table 4.5 Effects of mutations on 5’UTR features
5’ UTR Feature
Leader peptide: WT
Leader peptide: ValS-1
Terminator hairpin: WT
Terminator hairpin: ValS-5/6/11

MLNQYTEHQPTTSNIIILLYSLGLER*
MLNQYTEHQPTTSNIIIL*
CGTCCCAATAATATTGGGACGTTTTTTTAT
--------------------- TTTTTTTAT

We were curious to investigate whether the features in the ilvD 5’UTR are conserved across
S. aureus strains, and therefore compared the USA300 FPR3757 sequence to all complete
genome sequences of S. aureus (168). Overall, there was high sequence conservation
(Appendix A), however, several variants were identified in the putative regulatory regions
(Figure 4.11). Intriguingly, two variants occur in the putative ORF and both alter the number
of Leu codons in the peptide; mutation 14 results in a frame shift that deletes one Leu, and
mutation 15 changes a Leu codon to a Ser (Figure 4.11). Several sequence variants also occur
in the first CodY binding motif (CodY Box 1) (Figure 4.11). In addition, two strains,
HC1340 and Gv69, had a 1.8 kb transposase gene inserted between the 5’UTR and the start
codon of ilvD, and the terminator is deleted because of the insertion (Appendix A). It would
be of interest to investigate the consequence of these mutations on the level ilv-leu expression
and subsequent BCAA biosynthesis.

4.3.6

Absence of exogenous Ile restores growth in media lacking
Leu, but not Val

Altogether, our data point towards a model where both Ile and Leu contribute to ilv-leu
regulation, with Ile regulating the CodY-dependent mechanism, and Leu (and possibly Ile)
regulating attenuation (Figure 4.12). With this information in hand, we returned to our
growth assay where we grow S. aureus in the absence of exogenous BCAAs to test whether
we could induce synthesis by modulating Ile and Leu availability. We hypothesized that
omission of Ile from the growth medium would result in CodY-dependent de-repression of
the ilv-leu operon, and therefore would rescue the growth lag of S. aureus in media lacking
Leu or Val. Indeed, we found that the growth of S. aureus in CDM lacking Ile and Leu
initiated more rapidly than growth in CDM lacking Leu alone, suggesting that depletion of
Ile relieves ilv-leu repression (Figure 4.13A). Unexpectedly, S. aureus grown in CDM
lacking Ile and Val resembled growth of S. aureus in media lacking Val alone (Figure
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4.13B). Since the presence of Leu also contributes to repression of the operon, we further
examined growth of S. aureus in CDM lacking all three BCAAs, however the growth of S.
aureus remained attenuated, with no observable growth until a prolonged period of ~ 16 hr
(Figure 4.13C). Our promoter:reporter data suggest that ilvD expression is up-regulated in
media limited for all three BCAAs (Figure 4.7A,B), therefore we postulate that
posttranslational regulation of the ilv-leu operon controls BCAA synthesis under these
conditions.
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Figure 4.11 Mutations identified in the 5’UTR of ilvD
The ilvD 5’UTR was aligned across 168 complete S. aureus genomes. The location and
nature of the mutations identified are indicated, with the frequency in brackets. Mutations in
green are the SNPs identified in this study.
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Figure 4.12 Model of mechanisms regulating ilv-leu expression
Transcription of the ilv-leu operon is repressed by CodY. In the presence of Ile, CodY binds
and represses transcription. As Ile is depleted, CodY becomes inactive and expression of the
operon is induced. As the operon is transcribed, the ribosome beings translating the open
reading frame (ORF) upstream of ilvD. The ORF is rich in Ile and Leu and will stall if cells
are depleted of either tRNA. Stalling of the ribosome prevents formation of the terminator
hairpin, allowing transcription of the operon to proceed. When there is sufficient Ile/Leu
tRNA, the ORF is translated and the terminator hairpin forms, terminating transcription.
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Figure 4.13 Omission of Ile from CDM restores growth in media lacking Leu, but not
Val
A-C) Strains were pre-grown in complete CDM to mid-exponential phase and then subcultured into either complete CDM or CDM with amino acids omitted, as indicated. Data are
the mean +/- SD of three biological replicates.
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4.4 Discussion
In this study, we selected for genetic mutations that permit growth in media lacking Val to
identify the mechanisms regulating BCAA biosynthesis during growth of S. aureus in a
chemically-defined medium. Using this approach, we a trans-activing mechanism of
repression involving CodY and a cis-acting mechanim of repression involving a putative
attenuator peptide. We demonstrate that CodY-dependent repression responds to Ile
deprivation and that BrnQ2 is the predominant transporter to link exogenous Ile with CodY
activity. We postulate that the 5’UTR region of ilvD encodes a leader peptide that regulates
transcription by attenuation and responds to Leu deprivation and possibly Ile deprivation,
which are supplied by BrnQ1 and BcaP. Therefore, expression of the ilv-leu operon occurs
upon depletion of both Ile and Leu.
Attenuation regulates BCAA biosynthesis in E. coli and S. typhimurium (29–31), and
predicted attenuators can be found in various Gram-negative and Gram-positive bacteria (55–
57, 59). In support of attenuation regulation of ilv-leu in S. aureus, one of the mutations we
identified in our study occurs in the predicted leader peptide and changes a Leu codon to a
stop codon, which we predict would reduce Leu-dependent repression. The leader peptide
also contains three Ile, suggesting that the level of uncharged

Ile

tRNA also regulates ilv-leu

expression. In support of this, expression of the ilv-leu operon is increased upon exposure to
mupirocin, an antibiotic that binds to isoleucyl-tRNA synthetase and blocks the charging of
Ile

tRNA (60). It appears that CodY is the more dominant mechanism of repression, since S.

aureus exhibits a growth delay in media lacking Leu, but not Ile, suggesting that Leu
deprivation alone is not sufficient to relieve repression. Two additional CodY binding motifs
are present in the ilv-leu operon (18), and therefore transcription of downstream genes in the
operon would be expressed in a codY mutant, bypassing transcriptional termination at the
ilvD leader. Notably, these conditions did not select for mutations in other previously
described regulators of the ilv-leu operon, such as Gcp and YeaZ (41, 42). Since Gcp and
YeaZ are essential genes in S. aureus, we did not expect to isolate mutations in these genes,
however, we cannot rule out the possibility that the mutations in the 5’ UTR of ilvD reduce
binding of YeaZ to the promoter region (42).
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The fact that mutations in CodY are selected for when S. aureus is grown in the absence of
exogenous Val supports the notion that Val is not a relevant co-factor of CodY during growth
of S. aureus. This contradicts in vitro DNA-binding data, which suggest that all three BCAAs
bind to CodY and increase its DNA-binding activity to target gene promoters (21, 52, 53).
However, Ile has previously been suggested to act as the predominant BCAA to regulate
CodY activity during growth of S. aureus (17), B. subtilis (21), L. lactis (52), and L.
monocytogenes (61), and our data corroborate these observations in S. aureus strain USA300.
Further, we show that exogenous Ile is linked to CodY activity via the BrnQ2 transporter.
This is intriguing, as BrnQ1 and BcaP also transport Ile, warranting further investigation into
the mechanism that links BrnQ2 to CodY activity. BCAA transporters exist in other
organisms, yet none function, as BrnQ2 does, as a dedicated Ile-transporter (62–64). This
suggests that BrnQ2 might provide an advantage to the adaptation of S. aureus to Iledepleted environments. It is surprising that Leu and Val did not have even an indirect effect
on CodY-regulation of the ilvD promoter region, since Leu/Val deprivation has been shown
to trigger up-regulation of CodY target genes in a stringent response-dependent (i.e. GTP
depletion) manner in S. aureus (65). One might have predicted that if depletion of GTP was
required for de-repression of the ilv-leu operon, growth of S. aureus in the absence of Val
would select for mutations in genes involved in GTP synthesis (i.e. guaA or guaB), as has
been observed in B. subtilis (66). This might be related to strain differences in these studies
(Newman vs USA300) or slight differences in CDM composition (17, 65). Further
investigations into the connection between the stringent response and CodY activity as it
relates to ilvD expression in USA300 are required.
The codY mutations isolated in this study occur in the linker region of the protein. We
hypothesize that this might affect dimer formation and, consequently, DNA binding activity
(50, 67). Interestingly, the non-synonymous point mutation in ValS-10 did not result in a
codY mutant phenotype. This mutation might affect the binding affinity of CodY to its target
sequence, such that it no longer binds to target sequences upstream of the ilv-leu operon, but
retains its ability to bind to target sequences of other target genes, as CodY binding affinity
dictates the hierarchal expression of its target genes (16, 68). Genome sequencing of this
strain revealed a second point mutation in ribosome-binding factor A, however, we could
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complement this strain with codY in trans, supporting the conclusion that the codY mutation
is responsible for its growth phenotype.
We observed a disconnect between our model of transcriptional regulation and the growth
phenotype of S. aureus in media lacking all three BCAAs. Our model predicts that
expression of the ilv-leu operon would be de-repressed upon Ile and Leu deprivation, yet S.
aureus exhibits a significant growth lag in the absence of all three BCAAs. One possible
explanation for this observation is potential allosteric regulation of the BCAA biosynthetic
enzymes. The last gene in the ilv-leu operon, ilvA, encodes a threonine deaminase (TD),
which catalyzes the first step in Ile synthesis by converting threonine to -ketobuytrate. TD
is a pyridoxal phosphate (PLP)-dependent enzyme that contains an N-terminal catalytic
domain and a C-terminal regulatory domain. The C-terminal regulatory domain contains one
or two ACT-like sub-domains. The E. coli TD enzyme, which contains two ACT-like subdomains, is inhibited by Ile and activated by Val (69–71). The B. subtilis TD enzyme, which
contains one ACT-like sub-domain, is inhibited by Ile and it is proposed that Val activates
TD in the presence of Ile and inhibits TD at high concentrations (72). If TD activity in S.
aureus is most efficient in the presence of Val, it follows that Ile synthesis would be reduced
in the absence of Val. This could explain the absence of growth in media lacking Ile and Val.
It would be of interest to investigate whether TD in S. aureus is similarly subject to allosteric
regulation. Whether this is indeed the mechanism, the fact that S. aureus is unable to support
growth in conditions where Val is absent poses a challenge to S. aureus if it encounters this
environment in vivo and suggests that Val transport is critical for its growth. Indeed, we have
previously shown that BCAA transporters BrnQ1 and BcaP are required for S. aureus growth
in vivo (Chapters 2 and 3). Studies are ongoing to further understand the requirement of Val
acquisition for the growth of S. aureus in models of infection.
Altogether, this study details the molecular mechanisms regulating BCAA biosynthesis in S.
aureus and uncovers environments where S. aureus engages in BCAA biosynthesis. In doing
so, we reveal a predominant role for Ile in regulating CodY binding activity on the ilvD and
brnQ1 target sequences. Given the role of CodY in additionally regulating virulence genes,
these data suggest that environmental availability of Ile, sensed by BrnQ2, is an important
regulatory cue for S. aureus adaptation to nutrient limitation and virulence gene expression.
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Chapter 5

5

Concluding remarks and future directions

5.1 BCAA source preference in S. aureus
In the studies presented, we characterize the mechanisms S. aureus uses to maintain
intracellular levels of BCAAs and demonstrate the consequence of perturbing these
mechanisms on S. aureus physiology and virulence. We demonstrate that S. aureus represses
BCAA biosynthesis when an exogenous source of BCAAs is available and instead acquires
BCAAs through three dedicated transporters; BrnQ1, BrnQ2 and BcaP. The transporters are
required for growth in media where the BCAA source is free amino acids, but are not
required when a peptide source is added to the growth medium (Figure 3.7). It therefore
appears that when obtaining BCAAs, S. aureus prefers transport of BCAA-containing
peptides by oligopeptide or di/tri-peptide transporters to transport of free BCAAs, and
reserves synthesis for environments depleted of both sources. This contrasts other Grampositive organisms, like B. subtilis, where BCAAs are synthesized even in the presence of an
exogenous source (1). Although it appears that BCAA transporters are not required when a
peptide source is present, it cannot be ruled out that peptide transporters are up-regulated to
overcompensate for the loss of the permeases. Data from our laboratory and other research
groups indicate that acquisition of oligopeptides and di/tri-peptides in S. aureus is driven by
Opp3 and DtpT, respectively (Sheldon et al., unpublished data, (2)). Therefore, to fully detail
the relative importance of peptide transport vs BCAA transport, S. aureus strains deficient in
both peptide transport and BCAA transport will need to be characterized.
Our studies confirm that CodY regulates both BCAA transport and synthesis in S. aureus (3–
5). Given this, how does S. aureus achieve BCAA source preference? Waters et al., have
demonstrated that in the hierarchy of CodY regulation, BCAA transporters are de-repressed
upon moderate reductions in CodY activity, whereas de-repression of BCAA biosynthesis
genes requires more significant reductions in CodY activity (5). Since the extent of CodY
activity relates to availability of its ligands (GTP and BCAAs; of which we show Ile is the
most important (Figure 4.7)), it is evident that availability of exogenous Ile is an important
signal for the regulation of transport versus synthesis. In addition, we described a second
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mechanism governing BCAA synthesis that responds to Leu. This suggests that not only is
severe Ile depletion necessary for induction of synthesis, but also a simultaneous depletion of
Leu.
How does S. aureus cope if it encounters an environment depleted of only Leu or Val? A Val
limited environment in particular could prove challenging for S. aureus growth, since our
data indicate that a mutation is required to relieve repression of synthesis in this condition.
Leu and Val have both been shown to induce the stringent response, which depletes the other
CodY effector GTP, and consequently leads to CodY target gene de-repression in S. aureus
(6), however, we did not detect evidence of a stringent response-dependent de-repression of
the BCAA biosynthetic operon in our studies (i.e. the extended growth lags observed in the
absence of exogenous Leu or Val). One possible explanation for this difference might be
related to fact that the CDM used in our studies is more limited for amino acids than the
CDM used in the other studies (4, 6). As a result, the stringent response might be more active
in our conditions, causing CodY regulatory activity to primarily respond to Ile
concentrations. The differences could also be related to the different strains used in these
studies (Newman vs USA300). Nonetheless, the role of GTP in regulating BCAA transport
and synthesis via CodY requires further investigation. Notably, comparison of the ilvD
5’UTR from complete S. aureus genomes revealed mutations in the CodY binding motif and
the attenuator (Figure 4.11). It might prove interesting to investigate whether these mutations
affect the regulation of the ilv-leu operon. If these mutations help relieve repression of
synthesis, it could indicate that S. aureus does indeed encounter this conundrum in its natural
environment.
Additional studies are required to fully uncover the contribution of environmental and
synthesized BCAAs to S. aureus growth in vivo. In general, there is limited knowledge of the
BCAA requirement of pathogens during infection and the effect that perturbing these
mechanisms has on infection outcomes, and our studies provide the foundation for resolving
this. Our in vivo studies indicate that S. aureus encounters BCAA limitation in certain organs
(i.e. the heart (Figure 3.9)) and the nasal cavity (Figure 3.10), however S. aureus virulence is
only moderately attenuated, suggesting that peptide transport and/or synthesis also contribute
to growth at these infection sites. As eluded to in Chapter 3, we hypothesize that BCAA
synthesis is important for growth during murine nasal colonization. Human nasal secretions
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are limited for BCAAs, especially Ile (7), and peptides are also presumably limited because
S. aureus relies on methionine biosynthesis for growth in this niche (7). This hypothesis can
be tested by mutating a gene required for BCAA biosynthesis (i.e. ilvD) in a brnQ1bcaP
mutant. Strains with mutations in both synthesis and scavenging pathways would also be of
use in other animal models, such as our systemic infection model, given that the biosynthetic
operon is significantly induced during S. aureus growth in human serum and blood (8). Our
laboratory is also poised to examine the role of peptide transport in supplying BCAAs, as we
have characterized the phenotypes associated with mutations in the oligopeptide transporter
(opp3) and the di/tri-peptide transporter (dtpT). These mutations, coupled with either BCAA
transporters or synthesis, would allow for a comprehensive study of the relative contribution
of BCAA scavenging vs synthesis systems in different infection models, including a wound
model, pneumonia, sepsis and skin abscess. One limitation of using single gene mutations to
dissect this problem is that the strategies S. aureus employs to obtain BCAAs in vivo are
likely dynamic. It is not fully understood what threshold concentrations of Ile or Leu are
required for repression of synthesis via the mechanisms we identified, and it is likely that
there are waves of synthesis that correlate with fluctuations in the extracellular availability of
BCAAs. To fully appreciate the adaptability of S. aureus as it encounters changing
environments, an ideal approach moving forward would be to monitor the infectious process
in real-time using in vivo imaging technologies and to measure the kinetics of geneexpression using promoter:reporter systems. These studies would be insightful towards
understanding the environments where pathogens encounter nutrient limitation and how they
overcome this, which might inform efforts to develop novel therapeutics.

5.2 Does transporter specificity provide an adaptive
advantage in S. aureus?
An intriguing finding of our studies is the specificity of a given transporter for supporting a
certain physiological role of BCAAs. This is best exemplified by the results of the fatty acid
membrane analysis of each of the transporter mutants. BcaP functions as a Leu and Val
transporter as evidenced by the C14-uptake and growth assays (Figure 3.2 and Figure 3.5),
and yet BcaP-dependent Leu and Val transport does not contribute to the synthesis of Leuand Val-derived BCFAs. Therefore, it remains to be determined how S. aureus differentiates
between Leu and Val transported by BrnQ1 versus BcaP. A similar phenomenon is observed

161

with CodY regulation; although all three transporters contribute to Ile uptake, CodY activity
is most effected in response to BrnQ2-dependent Ile depletion. Such detailed analysis of
transporter function as it relates to bacterial physiology (aside from growth) are limited, if
not non-existent. Of closest comparison is a recent study in B. subtilis, that demonstrated that
CodY activity is diminished in a strain lacking all three BCAA transporters identified in this
species to date (1). All three transporters are capable of Ile transport, the predominant BCAA
to regulate CodY activity in this species as well (9), thus it might prove interesting to
investigate the effect of each on CodY activity individually. Studies investigating the
localization of transporters in the membrane or assessing protein-protein interactions might
help explain the link between an individual transporter and the physiological role of BCAAs.
Whatever the mechanism may be, the data support a clear distinction between transporters
supporting nutritional needs (BrnQ1 and BcaP) and transporters supporting regulatory needs
(BrnQ2). It is tempting to speculate that this distinction, accomplished by the evolution of a
dedicated Ile transporter, might confer a fitness advantage, whereby BrnQ2 provides a direct
connection between exogenous availability of the most predominant CodY effector, Ile, to
endogenous CodY activity. No other BrnQ or BcaP homologs described to date exhibit such
substrate specificity (Table 1.2, Table 1.3). To fully appreciate the link between BrnQ2 and
CodY-dependent virulence gene regulation, it would be beneficial to compare the
transcriptomes of a brnQ2 mutant to that of a codY mutant. Ile has previously been shown to
relieve CodY-dependent repression of the hyaluronidase virulence factor in S. aureus (10)
and describing the exact mechanism governing this would prove novel towards
understanding the role of exogenous BCAAs in regulating virulence gene expression. It is
also of interest to evaluate the virulence of the brnQ2 mutant in various animal models to test
the hypothesis that levels of Ile in host environments regulate S. aureus virulence. Mouse
models of skin infection and necrotizing pneumonia would be of priority, since decreased
CodY activity in these environments has drastic consequences on S. aureus virulence (11). If
a brnQ2 mutant mimics a codY mutant in these models, it would indicate that the murine skin
and lung environments are high in Ile and CodY is typically active. Another interesting
environment to explore is the intracellular environment. Host cytosolic Ile is an important
metabolic cue for intracellular infection of pathogen L. monocytogenes in a CodY-dependent
manner (12), and S. aureus can survive and replicate within the macrophage phagolysosome
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(13). It would be of interest to investigate whether Ile similarly acts as a metabolic signal for
S. aureus. One of the main challenges limiting the study of CodY regulation in vivo is that it
functions primarily a repressor in S. aureus; that is to say, a WT and codY mutant strain
would behave the same in any environment where low CodY activity is required for
replication and virulence. Although variants of CodY with reduced regulatory activity have
been generated, the opposite, variants with increased regulatory activity, have proved
difficult to generate (14). A full appreciation for CodY regulation will therefore likely require
real-time monitoring of CodY target gene expression in vivo using luminescent or fluorescent
promoter:reporter strains. With this system, it would be of high interest to investigate CodY
regulation in the nasal cavity. Human nasal secretions are nutrient limited, especially for Ile
and, as a consequence, S. aureus up-regulates metabolic genes, including amino acid
synthesis genes, when grown in a synthetic nasal medium (7). The low Ile availability might
be key to regulating its adaptation to this host environment.

5.3 Conclusion
The survival of S. aureus in diverse host environments reflects its ability to adapt to physical
and nutritional changes, yet the molecular mechanisms that facilitate this adaptation have
remained incompletely understood. This thesis investigated unanswered questions related the
initial stages of this adaptation – including what strategies does S. aureus have available to
acquire metabolites in nutrient deprived environments, how does it regulate which strategy it
employs, and how does nutrient availability contribute to virulence gene regulation to
promote S. aureus survival. Specifically, this research focused on the BCAAs given their
importance for S. aureus growth (i.e. protein synthesis and BCFA synthesis) and
environmental adaptation via CodY.
This work provides the first detailed description of how S. aureus obtains BCAAs and
discerns what mechanisms best serve the various physiological roles of BCAAs in the cells.
The implications of this are two-fold; first, the identification and characterization of BrnQ1
and BcaP implicates these transporters as important nutrient scavenging systems for protein
and BCFA synthesis. Their requirement for S. aureus infection and colonization indicates
that S. aureus does indeed encounter BCAA limitation in vivo and that these transporters are
necessary for exploitation of host sources of BCAAs. These advancements lay the foundation
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for future studies to continue to investigate the contribution of these transporters in additional
host environments, with the potential of revealing infection sites where therapeutics targeting
BCAA metabolism could be used to reduce S. aureus replication. Second, the elucidation of
the mechanisms regulating BCAA biosynthesis reveal a novel regulatory pathway involving
the Ile-specific transporter BrnQ2 that links exogenous Ile availability to CodY activity.
These data suggest that Ile is an important cue for the adaptation of S. aureus to nutrient
limitation, and might also potentially serve as an important cue for virulence gene regulation.
Altogether this work advances the knowledge of S. aureus basic biology, revealing important
growth and adaptation strategies necessary for survival in the human host.
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Appendix
Appendix A: BLAST sequence alignment of S. aureus ilvD 5’UTR
Straina
Staphylococcus aureus strain USA300-SUR24
Staphylococcus aureus strain USA300-SUR23
Staphylococcus aureus strain USA300-SUR22
Staphylococcus aureus strain USA300-SUR21
Staphylococcus aureus strain USA300-SUR20
Staphylococcus aureus strain USA300-SUR19
Staphylococcus aureus strain USA300-SUR18
Staphylococcus aureus strain USA300-SUR17
Staphylococcus aureus strain USA300-SUR16
Staphylococcus aureus strain USA300-SUR15
Staphylococcus aureus strain USA300-SUR14
Staphylococcus aureus strain USA300-SUR13
Staphylococcus aureus strain USA300-SUR12
Staphylococcus aureus strain USA300-SUR11
Staphylococcus aureus strain USA300-SUR10
Staphylococcus aureus strain USA300-SUR9
Staphylococcus aureus strain USA300-SUR8
Staphylococcus aureus strain USA300-SUR7
Staphylococcus aureus strain USA300-SUR6
Staphylococcus aureus strain USA300-SUR4
Staphylococcus aureus strain USA300-SUR3
Staphylococcus aureus strain USA300-SUR2
Staphylococcus aureus strain USA300-SUR1
Staphylococcus aureus strain USA300-SUR5
Staphylococcus aureus strain SR434
Staphylococcus aureus subsp. aureus strain USA300_SUR1
Staphylococcus aureus subsp. aureus isolate Clinical isolate
Staphylococcus aureus subsp. aureus strain HG001
Staphylococcus aureus DNA, complete genome, strain: OC8
Staphylococcus aureus subsp. aureus strain 2148.CO1
Staphylococcus aureus subsp. aureus strain 5118.N
Staphylococcus aureus subsp. aureus strain 1625.CO1
Staphylococcus aureus subsp. aureus strain 1969.N
Staphylococcus aureus subsp. aureus strain 1971.CO1
Staphylococcus aureus subsp. aureus strain 2148.N

% Identity
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
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Staphylococcus aureus isolate Sa_Newman_UoM
Staphylococcus aureus strain V605
Staphylococcus aureus strain V521
Staphylococcus aureus strain FORC_012
Staphylococcus aureus strain UTSW MRSA 55
Staphylococcus aureus subsp. aureus strain Gv88
Staphylococcus aureus subsp. aureus strain Gv51
Staphylococcus aureus subsp. aureus strain Be62
Staphylococcus aureus subsp. aureus strain HC1335
Staphylococcus aureus strain HUV05
Staphylococcus aureus strain CA12
Staphylococcus aureus strain V2200
Staphylococcus aureus subsp. aureus strain USA300_2014.C01
Staphylococcus aureus subsp. aureus strain USA300_2014.C02
Staphylococcus aureus strain CA15
Staphylococcus aureus strain M121
Staphylococcus aureus subsp. aureus DSM 20231
Staphylococcus aureus subsp. aureus DNA
Staphylococcus aureus subsp. aureus DNA
Staphylococcus aureus strain 27b_MRSA
Staphylococcus aureus strain 25b_MRSA
Staphylococcus aureus strain 26b_MRSA
Staphylococcus aureus strain 33b
Staphylococcus aureus strain 31b_MRSA
Staphylococcus aureus strain 29b_MRSA
Staphylococcus aureus strain 2395 USA500
Staphylococcus aureus strain XN108
Staphylococcus aureus strain UA-S391_USA300
Staphylococcus aureus strain NRS 100
Staphylococcus aureus USA300-ISMMS1
Staphylococcus aureus subsp. aureus Z172
Staphylococcus aureus subsp. aureus CN1
Staphylococcus aureus Bmb9393
Staphylococcus aureus M1
Staphylococcus aureus subsp. aureus VC40
Staphylococcus aureus subsp. aureus T0131
Staphylococcus aureus subsp. aureus str. JKD6008
Staphylococcus aureus subsp. aureus TW20
Staphylococcus aureus subsp. aureus USA300_TCH1516
Staphylococcus aureus subsp. aureus str. Newman DNA

719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
719/719 (100%)
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Staphylococcus aureus subsp. aureus COL
Staphylococcus aureus subsp. aureus NCTC 8325
Staphylococcus aureus subsp. aureus USA300_FPR3757
Staphylococcus aureus subsp. aureus strain ATCC 6538
Staphylococcus aureus subsp. aureus strain UCI 28
Staphylococcus aureus subsp. aureus strain UCI62
Staphylococcus aureus strain AUS0325
Staphylococcus aureus strain FORC_027
Staphylococcus aureus strain 08-02300
Staphylococcus aureus strain NCCP14562
Staphylococcus aureus strain NCCP14558
Staphylococcus aureus strain ZJ5499
Staphylococcus aureus strain RIVM6519
Staphylococcus aureus strain ST20130943
Staphylococcus aureus strain ST20130942
Staphylococcus aureus strain FDAARGOS_159
Staphylococcus aureus strain NZAK3
Staphylococcus aureus DNA, strain: MI
Staphylococcus aureus DNA, strain: FDA209P
Staphylococcus aureus subsp. aureus strain GR2
Staphylococcus aureus strain SA564
Staphylococcus aureus strain HOU1444-VR
Staphylococcus aureus strain FCFHV36
Staphylococcus aureus genome assembly NCTC13435
Staphylococcus aureus strain 502A
Staphylococcus aureus subsp. aureus ST228, isolate
Staphylococcus aureus subsp. aureus ST228, isolate
Staphylococcus aureus subsp. aureus ST228, isolate
Staphylococcus aureus subsp. aureus ST228, isolate
Staphylococcus aureus subsp. aureus ST228, isolate
Staphylococcus aureus subsp. aureus ST228, isolate
Staphylococcus aureus subsp. aureus ST228, isolate
Staphylococcus aureus subsp. aureus ST228, isolate
Staphylococcus aureus subsp. aureus 11819-97
Staphylococcus aureus subsp. aureus ECT-R 2
Staphylococcus aureus 04-02981
Staphylococcus aureus subsp. aureus Mu3 DNA
Staphylococcus aureus subsp. aureus JH1
Staphylococcus aureus subsp. aureus JH9
Staphylococcus aureus subsp. aureus Mu50 DNA

719/719 (100%)
719/719 (100%)
719/719 (100%)
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
718/719 (99%),
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Staphylococcus aureus subsp. aureus N315 DNA
Staphylococcus aureus strain FORC_026
Staphylococcus aureus strain 08-02119
Staphylococcus aureus strain ST20130939
Staphylococcus aureus strain ST20130938
Staphylococcus aureus strain ST20130941
Staphylococcus aureus strain ST20130940
Staphylococcus aureus strain XQ
Staphylococcus aureus strain RKI4
Staphylococcus aureus strain 93b_S9
Staphylococcus aureus subsp. aureus JKD6159
Staphylococcus aureus subsp. aureus ED133
Staphylococcus aureus subsp. aureus ED98
Staphylococcus aureus subsp. aureus MW2 DNA
Staphylococcus aureus strain SJTUF_J27
Staphylococcus aureus strain MCRF184
Staphylococcus aureus subsp. aureus strain JS395
Staphylococcus aureus strain 79_S10
Staphylococcus aureus strain 144_S7
Staphylococcus aureus subsp. aureus strain ATCC 25923
Staphylococcus aureus subsp. aureus 6850
Staphylococcus aureus subsp. aureus 55/2053
Staphylococcus aureus CA-347
Staphylococcus aureus subsp. aureus LGA251
Staphylococcus aureus subsp. aureus TCH60
Staphylococcus aureus strain MSSA476
Staphylococcus aureus strain 71A_S11
Staphylococcus aureus subsp. aureus ST772-MRSA-V strain DAR4145
Staphylococcus aureus subsp. aureus strain FORC_001
Staphylococcus aureus genome assembly Staphylococcus_aureus_ILR
Staphylococcus aureus strain SA40TW
Staphylococcus aureus subsp. aureus SA268
Staphylococcus aureus subsp. aureus strain H-EMRSA-15
Staphylococcus aureus subsp. aureus SA40
Staphylococcus aureus subsp. aureus SA957
Staphylococcus aureus subsp. aureus HO 5096 0412
Staphylococcus aureus subsp. aureus M013
Staphylococcus aureus subsp. aureus strain MRSA252
Staphylococcus aureus strain 08S00974
Staphylococcus aureus strain NZ15MR0322

718/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
717/719 (99%),
716/719 (99%),
716/719 (99%),
716/719 (99%),
717/720 (99%),
717/720 (99%),
716/719 (99%),
716/719 (99%),
716/719 (99%),
716/719 (99%),
716/719 (99%),
716/719 (99%),
716/719 (99%),
715/719 (99%),
716/720 (99%),
715/719 (99%),
715/719 (99%),
714/719 (99%),
714/719 (99%),
714/719 (99%),
714/719 (99%),
714/719 (99%),
714/719 (99%),
714/719 (99%),
714/719 (99%),
713/719 (99%),
713/719 (99%),
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Staphylococcus aureus subsp. aureus Tager 104
Staphylococcus aureus strain RIVM3897
Staphylococcus aureus strain RIVM1607
Staphylococcus aureus 08BA02176
Staphylococcus aureus subsp. aureus ST398
Staphylococcus aureus subsp. aureus strain LA-MRSA ST398 isolate
Staphylococcus aureus strain RIVM1295
Staphylococcus aureus subsp. aureus 71193
Staphylococcus aureus strain BB155
Staphylococcus aureus strain SA17_S6
Staphylococcus aureus RF122
Staphylococcus aureus subsp. aureus strain HC1340
Staphylococcus aureus subsp. aureus strain HC1340

713/719 (99%),
713/719 (99%),
713/719 (99%),
713/719 (99%),
713/719 (99%),
712/719 (99%),
713/720 (99%),
712/719 (99%),
711/719 (99%),
710/719 (99%),
710/719 (99%),
562/562 (100%)
132/132 (100%)

Staphylococcus aureus subsp. aureus strain Gv69
Staphylococcus aureus subsp. aureus strain Gv69

562/562 (100%)
132/132 (100%)

a The

5’UTR sequence of ilvD from USA300 FPR3757 (719 bp) was aligned to all S. aureus
complete assembled genomes (168 as of May 7th 2017) using BLAST.
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